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Malaria is the most prevalent vector-borne parasitic disease worldwide 
and a major cause of death from infections.  There is a great need to develop a 
low cost vaccine for malaria to control transmission of infection and impact of 
disease, due to the emergence of anti-malarial resistance.  Two leading blood 
stage malarial vaccine candidates are the apical membrane antigen-1 (AMA-1) 
and the merozoite surface protein-1 (MSP-1).  The aim of this project is to 
express malarial antigens in tobacco plants via plastid transformation and deliver 
them by subcutaneous or oral gavage of minimally processed transplastomic 
tissue to evaluate their efficacy to elicit an immune response and protect against 
malarial infection.  Transplastomic lines expressing the malarial antigens fused to 
the transmucosal carrier Cholera toxin B subunit (CTB-AMA-1) and CTB-MSP-1 
were generated. CTB-AMA-1 and CTB-MSP-1 accumulated up to 9.5% and 2% 
of the total soluble protein, respectively.  Chloroplast-derived CTB-AMA-1, CTB-
MSP-1, or both antigens were administered to BALB/c mice orally or by 
subcutaneous injections.  The immune response in the experimental animals 
compared to the control animals was found to be significant.  Using an 
immunofluorescence assay (IFA) and immunoblot, anti-AMA-1 and anti-MSP-1 
found in sera of immunized mice recognized the native parasite and the native 
parasite protein, respectively.  Anti-malarial antibodies inhibited parasite invasion 
into erythrocytes by utilizing an in vitro parasite inhibition assay.  Results of these 
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INTRODUCTION 
 Malaria is a vector-borne protozoan disease and four different species of 
the genus Plasmodium affects humans (P. falciparum, P. vivax, P. ovale, P. 
malariae) with P. falciparum the most virulent species causing the majority of 
morbidity and mortality across the world.  More than 2 billion people are at risk 
for malaria with approximately 500 million cases and 1 million deaths annually, 
mainly in children in sub-Saharan Africa (Greenwood, Fidock et al. 2008; 
Langhorne, Ndungu et al. 2008).  Malaria has become a prominent public health 
issue for the international health community and an effective malaria control 
program is imperative (Greenwood, Bojang et al. 2005).   
Plasmodium Life Cycle 
 Malaria parasites multiply in female Anopheles mosquitoes and are 
transmitted to humans when a mosquito takes a blood meal.  Plasmodium 
sporozoites, alongside saliva, enter the bloodstream, migrate to the liver, and 
then enter hepatocytes where amplification lasts for 2 to 9 days, hence the exo-
erythrocytic cycle (Langhorne, Ndungu et al. 2008).  Malaria parasites 
differentiate into thousands of merozoites, following rupture of liver cells, where 
they invade RBCs and initiate the asexual erythrocytic stage of the life cycle.  
The ring stage of parasite develops into a trophozoite and matures into 
schizonts, which ruptures and releases merozoites approximately 48 and 72 
hours, depending on the species of Plasmodium (Langhorne, Ndungu et al. 
2008).   The blood stage parasites are responsible for the clinical manifestations 
such as fever and severe malaria.  Some parasites develop into sexual 
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erythrocytic male (microgametocytes) and female (macrogametocytes) 
gametocytes, which fuse to form an ookinete, after a mosquito takes a blood 
meal and ingests the gametocytes.  The sporogonic cycle begins when the 
parasites multiply in the mosquito gut.  Ookinetes develop into oocysts in the 
midgut wall of the mosquito, which grow, rupture, and release sporozoites.  Once 
the sporozoites migrate to the mosquito’s salivary glands, they are ready to infect 
a new human host to continue the malaria life cycle. 
Clinical Manifestations of Malaria 
 The most common symptoms of malaria include flu-like illness such as 
fever, shivering, vomiting, nausea, joint pain, muscle aches, and headaches.  
The classical symptom of malaria is the sudden coldness with shivering followed 
by fever and then sweating persisting six to ten hours that occurs in cycles due 
the asexual erythrocytic stage of the Plasmodium spp. life cycle.  Other 
symptoms experienced by malaria patients include dizziness, malaise, myalgia, 
abdominal pain, mild diarrhea, and dry cough.  The causative organism of severe 
malaria is P. falciparum and consequences include coma and death if untreated.  
Other complications of severe malaria may occur and include splenomegaly, 
cerebral ischemia, hepatomegaly, hypoglycemia, hemoglobinuria, renal failure, 
pulmonary edmea, and acidosis.  Young children and pregnant women are most 
vulnerable to severe malaria along with individuals with no or decreased 
immunity.  Severe malaria is considered a medical emergency and should be 
treated urgently because it can rapidly progress to death within hours or days 
(Trampuz, Jereb et al. 2003).  
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Diagnosis and Treatment of Malaria 
 The number of cases of malaria is increasing and drug resistance is 
common so prompt diagnosis is essential to reduce morbidity and mortality 
(Yamey 2004).  Clinical diagnosis of patients involve examination of symptoms 
but the “gold standard” from a laboratory perspective is examining a blood smear 
stained with Geimsa stain via microscopic examination (Icke, Davis et al. 2005).  
If a microscope and staining reagents are not available and lack of quality 
microscopy, modern antigen detection kits such as a “dipstick” and molecular 
techniques can be used as alternative in diagnosis (Greenwood, Bojang et al. 
2005; Icke, Davis et al. 2005).  Several issues have evolved with using antigen 
detection kits and molecular practices such as cost-benefit ratio, accuracy of 
results, and adequate performance in field conditions. 
 Malaria needs to be recognized without delay in order to treat the patient 
and prevent further disease transmission.  Treatment of malaria can be 
conducted without hospitalization but if severe malaria persists hospitalization 
should be advised if possible.  Several antimalarial drugs are available for 
treatment such as chloroquine, sulfadoxine-pyrimethamine, mefloquine, quinine, 
artemisinin and doxycycline but combination treatment is ideal.  The combination 
of drugs is preferred because different modes of action are included to hopefully 
inhibit the emergence of drug resistant parasites (Greenwood, Bojang et al. 
2005).  Many factors should be considered when treating a patient with malaria 
such as species of infecting parasite, demographic region, cost, pregnancy, pre-
existing conditions, and drug allergies.  
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Need for an Antimalarial Vaccine 
 Preventing mosquito bites with mosquito nets or insect repellents, 
spraying insecticides, can reduce malaria transmission or expensive prophylactic 
drugs but resurgence of the parasite continues.  The causes of resurgence 
includes drug resistance to common antimalarials such as chloroquine, 
antifolates, sulfadoxine, and artemisin; mosquito’s resistance to widely used 
insecticides, pharmaceutical’s lack of interest in developing new drugs, 
implementing effective control measures, increase of tourism, and migration of 
non-immune populations to malaria endemic areas (Aide, Bassat et al. 2007; 
Hyde 2007).  A traditional public health tool to effectively reduce the tremendous 
disease burden would be to develop an efficacious antimalarial vaccine (Doolan 
and Stewart 2007).  Vaccination is one of the most effective means of preventing 
disease transmission, cost-effective in reducing new infections, and is easily 
administered.  Many concerns arise when developing an effective vaccine such 
as complexity of antigens Plasmodium presents throughout the different stages 
of its life cycle, high polymorphism among parasitic proteins, no appropriate 
animal model to test the efficacy of a vaccine, high cost of designing a vaccine, 
and length of vaccine development before it can be marketed by pharmaceutical 
companies (Aide, Bassat et al. 2007).  Currently, there is no licensed effective 
vaccine for the prevention of malaria.  The desirable vaccine to prevent malaria 
progression would consist of multi-antigens from different phases of the life cycle.  
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Malaria Vaccines are Feasible 
 There are four main arguments supporting the belief that a malaria 
vaccine is feasible (Aide, Bassat et al. 2007).  Individuals living in endemic areas 
progressively exhibit naturally acquired immunity by developing partial immunity 
against severe malaria (Gupta, Snow et al. 1999).  Individuals may still become 
infected with malaria but clinical manifestations and symptoms may be non-
existent due to suppression of parasitemia to undetectable levels (Webster and 
Hill 2003).  Passive transfer of antibodies from either immune malaria patients or 
maternal transmission during pregnancy has protected patients exposed to the 
parasite (Sabchareon, Burnouf et al. 1991) or newborn infants (Ballou, Arevalo-
Herrera et al. 2004), respectively.  In the 1970s, experiments were carried out on 
non-immune volunteers that were exposed to UV irradiated-weakened 
sporozoites and re-challenged by normal sporozoites with 90% of cases 
exhibiting short-lived immunity (Rieckmann, Beaudoin et al. 1979).  Several 
studies have reported the efficacy of recent development of protective malaria 
vaccine candidates in humans (Greenwood, Fidock et al. 2008; Maher 2008). 
Candidates for Malaria Vaccine 
 Due to the complexity of the malaria life cycle, vaccines can be targeted to 
the different stages beginning with the initial stage, exo-erythrocyctic.  The 
ultimate goal in vaccine development targeting the exo-erythrocyctic stage are 
the sporozoites and liver stage parasites to completely prevent infection 
(Greenwood, Fidock et al. 2008) by protecting against invasion of hepatocytes or 
inhibiting parasite development in hepatocytes.  Antibodies elicited at this stage 
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would either kill the sporozoite or block hepatocyte invasion.  Disrupting parasite 
development in infected hepatocytes would involve cytotoxic T-lymphocyte 
mediated lysis.  The earliest and now the most advanced pre-erythrocytic studied 
vaccine candidate utilizes CSP as a target because it is the most abundant 
surface antigen at this stage (Greenwood, Bojang et al. 2005).  Current vaccine 
trials utilizing CSP consists of a hybrid with the hepatitis-B surface antigen and a 
three-component adjuvant, AS02, known as RTS,S/AS02A but has provided only 
short-term protection  (Greenwood, Bojang et al. 2005).  Other antigens in clinical 
trials include TRAP and LSA but with disappointing results (Maher 2008).    
 Another strategy in vaccine development could target the second phase of 
the life cycle, erythrocytic, also known as the asexual blood phase.  Vaccines 
targeted at this stage are designed to prevent disease not infection by reducing 
the number of blood stage parasites (Greenwood, Fidock et al. 2008).  The 
vaccine could either prevent merozoite multiplication or invasion of RBCs, with 
current research mainly focusing on antigens involved in erythrocyte invasion 
(Greenwood, Bojang et al. 2005).  Antibodies can be elicited to agglutinate 
merozoites before schizont rupture or blocking invasion of RBCs.  Current clinical 
trials are under way looking at several blood stage candidates such as AMA-1, 
MSP-1, and RESA (Greenwood, Bojang et al. 2005; Maher 2008). 
 A final approach in vaccine development is to target the last stage in 
development, referred as the sexual phase.  Vaccines, also known as 
transmission-blocking, targeted at this stage are important in reducing parasite 
transmission to others by preventing feeding mosquitoes from becoming infected 
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or sexual fusion of gametocytes in the midgut of the mosquito (Greenwood, 
Bojang et al. 2005; Saxena, Wu et al. 2007).  This is an indirect way of providing 
protection but it helps in reducing disease transmission in the community 
(Greenwood, Fidock et al. 2008).  Antibodies can be induced to kill gametocytes, 
interfere with fertilization of gametocytes, transformation of the zygote into 
ookinete, or egress of ookinetes into viable sporozoites.  The approach of using a 
transmission-blocking vaccine is usually combined with other vaccines targeting 
other stages (Greenwood, Fidock et al. 2008).  Current research on 
transmission-blocking vaccine candidates include Pfs 25/28, Pfs 48/45, and Pfs 
230 (Greenwood, Bojang et al. 2005; Saxena, Wu et al. 2007) and could play a 
role in reducing transmission in the population. 
Apical Membrane Antigen-1 (AMA-1) 
 AMA-1 is a leading asexual blood-stage vaccine candidate (Good, Kaslow 
et al. 1998) because it plays a crucial role in invasion of Plasmodium parasites.  
AMA-1 is a type I integral membrane protein (Remarque, Faber et al. 2008) and 
initially traffricked to micronemes as an 83 kDa precursor protein and 
proteolytically processed to PfAMA-166 before exportation to the merozoite 
surface.  AMA-1 has been implicated as playing a function in reorienting with the 
merozoite as the apical organelles and RBC membrane align during invasion 
(Mitchell, Thomas et al. 2004).  Animal and in vitro studies support the crucial 
role for AMA-1 during invasion of RBCs such as anti-AMA-1 antibodies inhibiting 
invasion via growth inhibition assays (Hodder, Crewther et al. 2001), antibody-
mediated inhibition of antigen processing (Dutta, Haynes et al. 2003), anti-AMA-1 
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antibodies found in exposed individuals via sero-epidemiological surveys 
(Thomas, Trape et al. 1994), and AMA-1 has conferred protection in 
immunization studies (Narum, Ogun et al. 2000).  A critical issue with the using 
AMA-1 as a vaccine candidate is it is highly polymorphic (Healer, Murphy et al. 
2004) and this reduces susceptibility to the action of inhibitory antibodies.  Even 
though AMA-1 exhibits high polymorphism the C-terminal region is highly 
conserved and can be blocked by inhibitory antibodies.  AMA-1 is not only found 
in asexual blood stage merozoites but also expressed by sporozoites and liver 
stage merozoites (Remarque, Faber et al. 2008).  Targeting AMA-1 as a vaccine 
candidate not only can reduce the risk of malaria infection causing clinical 
disease but also the possibilities of cellular immunity may be stimulated and 
reduction in exo-erythrocytic viability.  The current literature definitely supports 
the idea of AMA-1 and its potential as a vaccine candidate.   
Merozoite Surface Antigen-1 (MSP-1) 
 MSP-1 is another leading asexual blood stage vaccine candidate 
(Siddiqui, Tam et al. 1987) and is proposed to play a role in parasite invasion of 
RBCs (Blackman, Heidrich et al. 1990).  MSP-1 is a 195-kDa glycoprotein 
(Mehrizi, Zakeri et al. 2008) found on the merozoite surface, which undergoes 
two proteolytic cleavages for entry into RBCs.  The first cleavage occurs when 
the merozoite is released from an infected RBC resulting in four polypeptide 
fragments (83, 30, 38, and 42 kDa) and the second cleavage occurs during 
invasion of a RBC and involves the C-terminal 42 kDa fragment that is cleaved 
into 33 and 19 kDa polypeptides (Mehrizi, Zakeri et al. 2008).  MSP-119 stays 
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anchored to the merozoite surface via a GPI tail when RBC invasion takes place 
(Chenet, Branch et al. 2008). The C-terminal portion of MSP-119 is a target of 
some monoclonal antibodies because they inhibit the growth of parasites in vitro 
(Uthaipibull, Aufiero et al. 2001) and has shown to provide protective immunity 
(O'Donnell, de Koning-Ward et al. 2001).  Vaccines based on the C-terminal 
region of MSP-1 including MSP-142 and MSP-119 have provided protection after 
parasite challenge in Aotus monkeys (Kumar, Yadava et al. 1995; Chang, Case 
et al. 1996), antibodies have been shown to inhibit RBC invasion and parasite 
growth (Blackman, Heidrich et al. 1990; Chang, Case et al. 1996), and anti-MSP-
119 has been correlated to clinical immunity with reduced parasite numbers and 
febrile illness (Branch, Udhayakumar et al. 1998).  A limiting factor in asexual 
stage vaccine development is that the C-terminal fragments of MSP-1 parasites 
isolated in different geographical areas have displayed sequence variation 
(Mehrizi, Zakeri et al. 2008).  Previous studies have provided the insight of using 
MSP-1 as a potential malaria vaccine candidate.       
The Use of Plants for an Anti-Malarial Vaccine 
There needs to be alternative approach in preparing an effective vaccine 
to enhance expression levels and potentially protection against malaria infection.  
Commonly used expression systems such as yeast, bacteria, mammalian cells, 
and baculovirus have expressed several malarial antigens but with the era of 
biotechnology other expression systems are being developed.  Plants could be 
considered as an optimal expression system because they can reduce cost due 
to the expense of fermentation, purification, processing, cold storage, 
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transportation, and delivery (Ruhlman, Ahangari et al. 2007; Arlen, Singleton et 
al. 2008).  The genetic manipulation of tobacco is highly achievable and yields 
large biomass and the success could be extended to other edible crops such as 
carrot, tomato, or lettuce.  Oral delivery of plant-derived vaccines has been 
shown to induce both mucosal and systemic immunity (Nochi, Takagi et al. 2007; 
Verma and Daniell 2007).  The genetic engineering of plants could establish a 
cost-effective approach in vaccine development to poor, developing countries 
where malaria infection is most severe. 
Advantages of Chloroplast Genetic Engineering 
Many crop species have been genetically modified to express human 
therapeutic proteins via the nuclear genome but expression levels of the foreign 
protein are inefficient to purify or oral deliver.  Chloroplast genetic engineering 
has been a targeted approach to overcome the concerns of using nuclear 
transformation such as high level expression of foreign proteins due to thousands 
of genomes per cell (De Cosa, Moar et al. 2001; Daniell, Khan et al. 2002), gene 
containment (Daniell 2002; Daniell 2007), gene silencing and position effect (De 
Cosa, Moar et al. 2001), pleiotropic effects (Daniell, Lee et al. 2001), and multi-
gene expression (De Cosa, Moar et al. 2001; Quesada-Vargas, Ruiz et al. 2005) 
in a single transformation event.  Chloroplast transformation technology has 
contributed in the medical advancement such as expressing proteins in disease 
resistance (DeGray, Rajasekaran et al. 2001), biopharmaceuticals (Staub, Garcia 
et al. 2000; Fernandez-San Millan, Mingo-Castel et al. 2003; Arlen, Falconer et 
al. 2007; Ruhlman, Ahangari et al. 2007), and vaccines (Daniell, Streatfield et al. 
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2001; Kamarajugadda and Daniell 2006; Arlen, Singleton et al. 2008); and in 
agriculture such as herbicide (Daniell, Datta et al. 1998) and insect resistance 
(Kota, Daniell et al. 1999), and phytoremediation of toxic metals (Ruiz, Hussein 
et al. 2003; Hussein, Ruiz et al. 2007) in transgenic plants.  Genetic engineering 
is achieved by stably integrating the flanking sequences of the foreign gene 
through homologous recombination with the intergenic regions of the chloroplast 
genome (Kumar and Daniell 2004).  The use of plastid transformation and 
chloroplast genetic engineering has allowed the expression of foreign genes at a 
level that is optimal for the oral delivery of vaccines.    
Vaccine Antigens Expressed via the Chloroplast Genome 
Several vaccine antigens have been expressed using the approach of 
chloroplast genetic engineering (Kamarajugadda and Daniell 2006).  The many 
advantages of expressing antigens in the chloroplast listed above supports the 
current rationale of producing transgenic lines expressing the vaccine antigen of 
interest.  Numerous vaccine antigens expressed via the chloroplast are targeted 
against bacterial, viral, and protozoan pathogens such as the plague F1-V fusion 
antigen (Arlen, Singleton et al. 2008), Entamoeba histolytica (Chebolu and 
Daniell 2007) anthrax protective antigen of Bacillus anthracis (Watson, Koya et 
al. 2004; Koya, Moayeri et al. 2005), VP6 protein of rotavirus (Birch-Machin, 
Newell et al. 2004), 2L21 peptide from the virulent canine parvovirus (CPV) 
(Molina, Hervas-Stubbs et al. 2004), and CTB for cholera (Daniell, Lee et al. 
2001).  The expression levels of the PA of anthrax was up to 14.2% of TSP and 
subcutaneous immunization of mice with partially purified chloroplast-derived PA 
  12
resulted in 100% survival after challenge with lethal doses of anthrax toxin (Koya, 
Moayeri et al. 2005).  The expression levels of the F1-V fusion antigen 
accumulated up to 14.8% of TSP and after challenge with aerosolized Yersinia 
pestis all control animals died in three days and 33% of animals receiving boosts 
of subcutaneous injections of F1-V and 88% of mice receiving oral boosts of F1-
V were protected (Arlen, Singleton et al. 2008).  This finding brings hope of 
utilizing the approach of chloroplast technology and oral-deliverable, cost-
effective vaccines closer to reality.       
Cholera Toxin B Subunit (CTB) 
The Gram-negative bacteria Vibrio cholerae secretes an enterotoxin 
known as cholera toxin.  CT is oligomer made up of six proteins AB5 consisting of 
one toxic 27 kDa A subunit and five non-toxic B subunits each weighing 11.6 kDa 
(Daniell, Lee et al. 2001).  This hexameric complex facilitates entry into the 
mucosal epithelia of the intestine via CTB and the GM1 ganglioside receptors 
(Daniell, Lee et al. 2001).  GM1 gangliosides are found on the gut epithelial 
surface and it is known CTB to have a high affinity to these glycosphingolipids 
(Mor, Gomez-Lim et al. 1998).  CTB is known when given orally to be a safe, 
potent, mucosal immunogen and adjuvant (Holmgren, Lycke et al. 1993). CTB 
has the potential to enhance the immune response when coupled to other 
pathogenic antigens (Daniell, Lee et al. 2001).  A previous study used CTB-GFP 
plants and oral administered the transgenic leaf material to mice and observed 
CTB in the intestinal wall and GFP fluorescence in mouse intestinal mucosa, 
liver, and spleen (Limaye, Koya et al. 2006)  This opens the possibility of oral 
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deliverable human therapeutic proteins via receptor-mediated oral delivery 
(Ruhlman, Ahangari et al. 2007).    
Bioencapsulation for Oral Delivery 
 A critical issue arises with the oral delivery of vaccine antigens into the 
body.  The antigen delivered needs to be intact and retain its biological activity 
and withstand the digestive enzymes present in the stomach.  Bioencapsulation 
is the process of plant cells’ ability to protect an oral-delivered protein from acid 
digestion (Walmsley and Arntzen 2000).  Oral delivery of vaccine antigens needs 
to cross the mucosal barrier effectively to provide protection in the event of the 
immune system encountering the pathogen.  Previous reports show that GFP 
fused with transmucosal carrier CTB was bioencapsulated because following oral 
administration of CTB-GFP leaf material both CTB and GFP was found in mouse 
intestinal cells (Limaye, Koya et al. 2006).   GFP but not CTB was present in the 
liver of mice after oral delivery indicating it was protected from the digestive 
enzymes of the stomach.  The role of receptor-mediated oral delivery and 
bioencapsulation provides insight in producing low-cost vaccines that deliver 




RATIONALE AND APPROACH 
 The primary objective of this project is to express and characterize the 
malarial antigens CTB-AMA-1 and CTB-MSP-1 via the chloroplast genome and 
evaluate the immunogenicity of the chloroplast derived antigens.  The novelty of 
this project is the approach of delivering the chloroplast-derived CTB-malarial 
antigens via oral delivery and comparing the immunogenicity to the typical route 
of administration of vaccines, through injection.  To achieve these objectives, 
malarial gene products need to be cloned into pLD-UTR for expression in plants.   
Using particle bombardment, transgenic lines need to be obtained to express the 
chloroplast-derived CTB-malarial antigens.  The chloroplast-derived proteins 
need to be quantified for enrichment for subcutaneous injection and delivery to 
rodents via oral gavage.  The immunogenicity of the mouse titers needs to be 
determined via ELISAs for the comparison of subcutaneous injection versus oral 
delivery.  The antibodies present in the immunized mouse sera will be tested with 
immunoblot and IFA analysis to determine recognition of native parasite protein 
and native parasite, respectively.  If the antigens are immunogenic, they will be 








MATERIALS AND METHODS 
Amplification of AMA-1 and MSP-1 in Asexual Stages and Cloning 
 Based on the C-terminal regions of AMA-1 and MSP-1 (Pan, Huang et al. 
2004), forward and reverse primers were designed to amplify the gene.  The total 
RNA used for RT-PCR was isolated prior (stored at -80°C) by harvesting an 
asynchronous 3D7 P. falciparum parasite culture with 0.05% saponin lysis and 
isolating total RNA by using the RNAgents Total RNA Isolation System 
(Promega).  The forward primers designed were (5’-CCCGGGGCCAAGAAAA-
AGAAGAGCTTTGTCCCATCCCAT-3’) with a SmaI site and Furin Cleavage site 
(Arg-Lys-Arg-Arg) and (5’-CCCGGGGCCAATTTCACAACACCAATG-3’) with a 
SmaI site for AMA-1 and MSP-1, respectively.  The reverse primers designed 
were (5’-CGGCGGCCGCTTTCATGTTATCATAAGTTG-3’) and (5’-ATAAGAA-
TGCGGCCGCTTAGTTAGAGGAACTGCAGAAAA-TAC-3’) with a NotI site for 
AMA-1 and MSP-1, respectively.  The StrataScript one-tube RT-PCR system 
(Stratagene) with Easy-ATM High-Fidelity PCR Cloning Enzyme was used to 
reverse transcribe and amplify the genes using 200 ng of total RNA and the 
gene-specific primers.  RT-PCR cycling conditions were as follows: 1 cycle of 
reverse transcription at 42°C for 30 minutes followed by transcriptase enzyme 
inactivation at 95°C for 30 seconds; 5 cycles of denaturation at 95°C for 30 
seconds, annealing at 50°C for 30 seconds and extension at 68°C for 6 minutes; 
35 cycles at 95°C for 30 seconds, 58°C for 30 seconds and 65°C for 6 minutes 
and 1 cycle at 65°C for 10 minutes.  5 µL of RT-PCR products were analyzed by 
electrophoresis on a 0.8% agarose gel and visualized by the Gel Doc 2000 (Bio 
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Rad).  The remainder of the RT-PCR product was purified with the QIAquick 
PCR Purification Kit (Qiagen) and confirmed by a 0.8% agarose gel.  The genes 
were cloned into the pGEMT Easy Vector (Promega) and the presence of the 
insert was confirmed by digestion with EcoRI and gel electrophoresis.  The DNA 
was sent to the University of Florida: DNA Sequencing (ICBR: The Biotechnology 
Program) facility for sequencing.  Accuracy of the insert sequence was confirmed 
by using the DNA STAR SeqMan program. The FC AMA-1 and MSP-1 genes 
were subcloned into the pBSK+ (Stratagene) vector by using the SmaI and NotI 
restriction sites.  
Amplification and Cloning of CTB 
Template DNA containing the CTB gene was provided by Dr. Daniell’s lab.  
The CTB gene was amplified via PCR with a forward primer (5’-
CCGCTCGAGCATATGACACCTCAAAATATTACT-3’) with XhoI and NdeI sites 
and a reverse primer (5’-CCCGGGCCATTTGCCATACTAATTGC-3’) with a SmaI 
site.  The CTB gene was cloned into the pGEMT Easy Vector (Promega) and the 
sequence was confirmed.  CTB was subcloned into the pBSK+ vector using the 
XhoI and SmaI restriction sites.  The pBSK+ CTB, pBSK+ FC AMA-1, and 
pBSK+ MSP-1 were digested with SmaI and NotI restriction enzymes and the FC 
AMA-1 and MSP-1 genes were ligated into the pBSK+ CTB plasmid to complete 
the fusion genes: CTB FC AMA-1 and CTB MSP-1. 
 
 
Chloroplast Plasmid Construction 
 The CTB FC AMA-1 and CTB MSP-1 transgenes in the pBSK+ vector 
were cut with NdeI and NotI restriction enzymes and ligated into the pLD-UTR 
vector with T4 ligase (New England BioLabs) and transformed into 
supercompetent E. coli XL-10 Gold cells.  The figure below demonstrates the 
proposed orientation of the transgene into the chloroplast vector.  
 
Figure 1: Chloroplast pLD-UTR CTB-Malarial Antigens (not drawn to scale) 
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Following transformation of chloroplast vector constructs into E. coli, 
colonies were selected and grown overnight in 5 mL of LB broth and 5 µL of 
ampillicin (100 mg/mL).  The DNA was isolated by using the QIAprep Spin 
Miniprep Kit (Qiagen), digested with NdeI and NotI restriction enzymes, and 
analyzed by a 0.8% agarose gel.  A positive clone containing the chloroplast 
vector construct was obtained from the glycerol stock and grown overnight.  The 
chloroplast plasmid DNA was purified with the QIAprep Plasmid Maxi Kit 
(Qiagen) and the DNA was analyzed by gel electrophoresis on a 0.8% agarose 
gel.  
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Generation of Transgenic Plants 
Preparation of Gold Particles 
 A mixture of 50 mg of gold particles and 1 mL of 100% ethanol was 
vortexed for two minutes and centrifuged at 10,000 x g for three minutes in a 1.5 
mL eppendorf tube.  The supernatant was discarded and the gold particles were 
resuspended in 1 mL of 70% ethanol for one minute.  The suspension was left at 
room temperature for fifteen minutes with mixing intermittently.  Centrifuging at 
5,000 x g for two minutes pelleted the gold particles and the supernatant was 
discarded.  The gold particles were vortexed with 1 mL of sterile distilled water 
and incubated at room temperature for one minute and centrifuged at 5,000 x g 
for two minutes.  The steps to wash the gold particles with sterile water were 
repeated three times (Kumar and Daniell 2004).  The gold particles were 
resuspended in 1 mL of sterile 50% glycerol and stored on ice until use. 
 50 µL of gold particles was removed from the stock and transferred into a 
1.5 mL microcentrifuge tube along with 10 µg of plasmid DNA.  To ensure proper 
binding of DNA to the gold particles 50 µL of 2.5 M CaCl2 and 20 µL of 0.1 M 
spermidine-free base was added.  The mixture was vortexed for twenty minutes 
at 4°C and the DNA-coated gold particles were centrifuged at 10,000 x g for one 
minute.  The supernatant was removed and the pellet was washed four times in 
200 µL of absolute alcohol.  The DNA-coated gold particles were resuspended in 
50 µL of 100% ethanol.  10 µL of vortexed DNA-coated gold particles were 
loaded onto sterile macrocarriers and allowed to air dry in the laminar air flow 
hood. 
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Bombardment of Leaf Tissue 
 The bombardment was performed under sterile conditions with all 
equipment including the gene gun (Bio-Rad PDS-1000/He) sterilized with 95% 
ethanol.  Green healthy leaves from the in vitro tobacco plant Nicotiana tabacum 
variety Petit Havana were cut from young plants and placed with the adaxial side 
facing up on autoclaved Whatman filter paper on the top of solidified RMOP 
medium.  The macrocarrier with the DNA-gold coated particles were placed on 
the macrocarrier holders.  The bombardment was performed at 1,100 psi and 28 
Hg.  After the bombardment, the transformed leaves were covered with 
aluminum foil and kept in the dark for 48 hours at room temperature (Kumar and 
Daniell 2004).  
Regeneration and Selection of Transplastomic Shoots 
 After 48 hours, the leaves were cut into 5x5 mm2 pieces and transferred to 
RMOP media (one pack of MS basal salt mixture, 30 g of sucrose, 100 mg myo-
inositol, 1 mL of 1 mg/mL BAP, 100 µL of 1 mg/mL NAA, 1 mL of thiamine 
hydrochloride to 1 L of sterile distilled water and adjusted to pH 5.8 using 1N 
KOH; 6g of phytagar was added to media to solidification; autoclaved and cooled 
before pouring into plates) containing 500 µg/mL of spectinomycin with the 
bombarded side in contact with medium.  The Petri dish was sealed with parafilm 
and kept in the culture room until putative transgenic shoots appear.  Confirmed 
positive transgenic lines by PCR analysis were subjected to second round of 
selection to achieve homoplasmy.  After four weeks on secondary selection, the 
shoots were transferred to MSO media (one packet of MS basal salt mixture and 
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30 g of sucrose to 1 L of sterile distilled water; prepared to pH of 5.8 using 1N 
KOH; 6 g of phytagar) with 500 µg/mL spectinomycin.  This accounts for the third 
round of selection and rooting. 
Isolation of Plant DNA and Confirmation of Transgene Integration 
Before proceeding to the next round of selection, 100 mg of leaf material 
was harvested from putative transplastomic shoots.  The QIAprep DNeasy Plant 
Mini Kit (Qiagen) was used to isolate plant genomic DNA, following the 
manufacturer’s protocol.  The procedure yields approximately 20-30 µg of DNA 
and the isolated DNA was used for PCR analysis.  PCR was used to confirm 
transgene cassette integration into the chloroplast genome by the primer pair 3P 
(5’AAAACCCGTCCTCEGTTCGGATTGC-3’) and 3M (5’CCGCGTTGTTTCAT- 
CAAGCCTTACG-3’) (Daniell, Ruiz et al. 2005).  The integration of the gene of 
interest was confirmed by PCR using the primer pair 5P (5’-
CTGTAGAAGTCACCATTGTTGTGC-3’) and 2M (5’-TGACTGCCCACCTGAG- 
AGCGGACA-3’) (Daniell, Ruiz et al. 2005).  DNA isolated from wild type Petit 
Havana was used as the negative control and DNA isolated from known 
transgenic plant material was used as the positive control.  For PCR analysis, 50 
µL of reaction volume was prepared in a 0.2 mL PCR tube: 1µL of 100 ng/µL 
genomic DNA, 5 µL of 10X PCR reaction buffer, 4 µL of 2.5 mM dNTP, 1 µL of 
3P and 3M primers (or 5P and 2M primers), 1 µL of Taq DNA polymerase, and 
sterile distilled water to make up the total volume.  The initial denaturation was 
set at 94° for 5 minutes and amplification was carried out for thirty cycles of the 
following program: 94°C for 1 minute (denaturation), 60°C for one minute 
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(annealing), and 72°C for 2 minutes (extension).  Final extension of ten minutes 
at 72°C was carried at the end of PCR.  To examine the PCR product via 
agarose gel electrophoresis, 5 µL of was loaded, along with controls, into a 0.8% 
agarose gel and visualized by the gel doc. 
Southern Blot Analysis to Identify Homoplasmic Plants 
Isolation of Plant Genomic DNA 
 Leaf material from transgenic and non-transgenic plants was removed 
with aseptic technique from the in vitro greenhouse and ground with liquid 
nitrogen into 100 mg of a fine powder.  Previously made and stored at 65°C, 1 
mL of DNA extraction buffer (Tris-HCl pH8, EDTA, NaCl, CTAB, BME up to 10 
mL of water) was added to the leaf material and incubated at 65°C for thirty 
minutes with gentle mixing every five to eight minutes.  667 µL of (48:2) 
chloroform:isoamyl alcohol was added to the homogenate with gentle inverting 
for one minute followed by centrifugation at 10,000 rpm for ten minutes.  The 
supernatant was collected and placed into new tubes and 667 µL of ice, cold 
isopropyl alcohol was added with gentle mixing to precipitate nucleic acid.  A 
visible, dense clump was seen and centrifuged for ten minutes at 10,000 rpm.  
The nucleic acid was washed twice with 70% ethanol and allowed to air dry at 
room temperature followed by further drying with the DNA 110 speed vac 
(Savant Instruments, Inc.) for five minutes.  The pellet was dissolved in 500 µL of 
0.1X TE (1mM Tris-HCl (pH 8) + 0.1mM EDTA (pH 8)) containing 0.1 µg/µL 
RNase and incubated at 37°C for thirty minutes.  500 µL of (24:25:1) of 
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chloroform:phenol:isoamyl alcohol was added and mixed thoroughly to visualize 
three layers and centrifuged for fifteen minutes at 12,000 rpm.  The upper layer 
containing the DNA was removed and placed into new tubes and the same 
volume of chloroform was added to remove phenol.  The tube was mixed 
thoroughly and centrifuged for fifteen minutes at 14,000 rpm.  Two layers were 
visualized and the top layer containing DNA was transferred to new tubes.  1 mL 
of 100% chilled ethanol and 33 µL (1/10th volume of DNA) of 3M Na Acetate, pH 
5.2 was added to allow precipitation of DNA.  The reaction was kept at -20°C for 
one hour and centrifuged for ten minutes at 14,000 rpm.  The supernatant was 
decanted very slowly with a visible white pellet remaining.  The pellet was 
washed with 70% ethanol and centrifuged for ten minutes at 14,000 rpm.  The 
pellet was dried with a DNA 110 speed vac (Savant Instruments, Inc.) for five 
minutes to remove remaining ethanol and dissolved in 100 or 200 µL 0.1X TE 
(1mM Tris-HCl (pH 8) + 0.1mM EDTA (pH 8)), depending on the pellet size.  The 
genomic samples were loaded on a 0.8% agarose gel to visualize the bands.  
The concentration of the DNA was determined by a spectrophotometer.  
Restriction Digestion of Genomic DNA 
 The transgenic and untransformed samples containing equal amounts of 
DNA were digested with ApaI in a reaction containing: 1.5 µg of DNA, 4 µL of 
10X BSA, 4 µL of 10X Buffer 4 (New England Biolabs), 2 µL of ApaI (New 
England Biolabs), and sterile distilled H20 to make up the volume of 40 µL.  The 
reaction was incubated overnight at 37°C.   
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Agarose Electrophoresis and DNA Transfer 
 Each of the 40 µL reaction volume samples was loaded on a 0.8% 
agarose gel and electrophoresis was run for 3 hours at 100 volts.  The gel was 
visualized with a fluorescent ruler.  The gel was depurinated with 0.3N HCl for 
ten minutes (until the color of the dye became yellow) and removed.  This was 
followed by immersing the gel into Hybridization Denaturing Solution (5 PRIME – 
3PRIME) for thirty minutes followed by a wash with sterile H20.  The gel was 
immersed with Hybridization Neutralization Solution (5 PRIME – 3 PRIME) for 
thirty minutes followed by a wash in transfer buffer (2X SSC, Eppendorf) for 5 
minutes.  The membrane (S & S Nytran: SuperCharge, Schleicher & Schuell) 
was immersed in sterile H20 for fifteen minutes and left in transfer buffer until use.  
The transfer of DNA from the agarose gel to membrane utilized the Turboblotter 
(Rapid Downward Transfer System/Buffer Tray, Schleicher & Schuell) protocol.  
Twenty sheets of dry GB004 paper, followed by four sheets of dry GB002, and 
one sheet of prewet, in transfer buffer, GB002 was placed in the stack tray.  The 
prewet transfer membrane was placed on the stack followed by the agarose gel 
on top.  A rolling pin was used to remove any air bubbles that were present.  The 
top of the gel was wet with the application of transfer buffer and three sheets of 
prewet GB002 paper was placed on top.  The buffer tray was attached to the 
stack tray and filled with 125 mL of transfer buffer.  The wick was placed on top 
of the stack so the ends would drape into the buffer tray.  The wick cover was 
placed on top to prevent evaporation and the transfer continued overnight at 
room temperature.  The following day, the membrane was marked with a pencil 
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and rinsed with transfer buffer for five minutes.  The membrane was placed on 
chromatography paper and allowed to air dry.  The membrane was cross-linked 
using the UV Stratalinker 2400 (Stratagene) at the setting autocrosslink and 
stored at a dry place until further use.          
Generation of Probes 
 The following PCR reaction was set up for the amplification of the 2P2M 
flanking sequence probe with the 2P primer (5’-GCGCCTGACCCTGAGATGTG- 
GATCAT-3’) and 2M primer (5’-TGACTGCCCAACCTGAGAGCGGACA -3’): 1 µL 
of DNA, 5 µL of 10X Buffer, 2.5 µL of MgCl2, 1 µL of dNTP, 1 µL of 2P primer, 1 
µL of 2M primer, 1 µL Taq polymerase, and 37.5 µL of sterile H20. The initial 
denaturation was set at 94° for 5 minutes and amplification was carried out for 
twenty-nine cycles of the following program: 94°C for 30 seconds (denaturation), 
61°C for 30 seconds (annealing), and 72°C for 1 minute and 30 seconds 
(extension).  Final extension of seven minutes at 72°C was carried at the end of 
PCR.  The 50 µL PCR reaction was loaded into a 0.8% agarose gel and 
visualized with the Bio Rad Gel Doc 2000.  The bands were excised and gel 
extracted with the QIAquick Gel Extraction Kit (Qiagen) by following the 
manufacture’s protocol and eluting with 35 µL of Buffer EB.  
Prehybridization of Membrane 
 Into the hybridization bottle, the membrane was placed with the side 
exposed to DNA facing inwards and 20 mL of prehybridization solution (36.5 mL 
of sterile water, 10 mL of 20X SSC, 2.5 mL of 100X Denhardt’s (6% Ficoll, 6% 
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polyvinylpyrrolidone, 6% BSA), 500 µL of 10% NaPPi, and 500 µL of 10% SDS) 
was added and incubated at 65°C with the Hybridiser HB-1D (Techne).   
Sonicated salmon sperm DNA (10 mg/mL) (Stratagene) was boiled for minutes 
and 500 µL was added into the hybridization bottle.  The pre hybridization of the 
membrane incubated at 65°C for four hours.  
Probe Labeling and Purification 
 The PRIME-It Random Primer Labeling Kit (Stratagene) protocol was 
followed to label the radioactive probe.  In a clean microcentrifuge tube: 20 ng of 
the flanking probe, 10 µL of random oligonucleotide primers, and up to 23 µL of 
sterile H20 was added and boiled for five minutes.  The mixture was briefly 
centrifuged at room temperature.  The following was added in order: 10 µL of 5X 
ATP buffer, 5 µL of Redivue (Alpha-32P) DATP, and 1 µL of Exo (-) Klenow 
(5U/µL) and mixed by stirring.  The mixture was heated for fifteen minutes at 
37°C followed by adding 2 µL of stop mix.  A NucTrap probe purification column 
(Stratagene) was placed in a push column device and a clean microcentrifuge 
tube containing 100 µL of salmon sperm DNA was placed below.  80 µL of 1X 
STE was injected into the column with a syringe and collected into the 
microcentrifuge tube.  The radiolabeled probe was added to the column and 
pushed through with a syringe followed by 80 µL of 1X STE.  The syringe was 
applied to the column once more and 300 µL of 1X STE was added to the 
purified probe.        
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Hybridization and Washing of Membrane 
 The purified probe was boiled for five minutes and added to the 
hybridization bottle with a sterile transfer pipette and allowed to hybridize with the 
membrane overnight at 65°C.  The following day, the membrane was washed 
twice, five minutes each with wash buffer #1 (2X SSC, 0.1% SDS, and 0.1% 
NaPPi) followed by washing with wash buffer #2 (0.2X SSC, 0.1% SDS, and 
0.1% NaPPi) four times, fifteen minutes each.  The wash buffer was discarded 
into the P32 waste and the membrane was allowed to air dry behind the plastic 
shield.  The radioactive membrane was wrapped with saran wrap and a ladder 
(Stratagene) was placed on front.      
Autoradiography 
 The film cassette along with the hybridized blot was taken to the dark 
room and under safe, red light the blot was placed faced down onto the 
intensifier screen and the BIOMAX MS Film: Maximum Sensitivity (Kodak) was 
placed in between the screen.  The cassette with the hybridized blot and the film 
was incubated at -80°C.  The next day the cassette was taken out of the -80°C 
freezer to thaw and the film was developed with the X-ray film processor. 
Characterization of Expressed Chloroplast-Derived Proteins  
Extraction of Protein from Transformed Tobacco Leaves 
 Mature leaf material was harvested around four to five o’clock in the early 
evening hours.  Leaves were washed in the lab and allowed to air dry and stored 
at -80°C until further use. Chloroplast-derived CTB-malarial proteins from 
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transgenic lines was extracted by grinding 100 mg of plant tissue with a mortar 
and pestle in liquid nitrogen and fine powdered leaf material was placed in a 1.5 
mL microcentrifuge tube with a hole poked through the top.  The microcentrifuge 
tube was immediately placed in liquid nitrogen until further use.  200 µL of plant 
extraction buffer (100mM NaCl, 10mM EDTA, 200mM Tris-HCl pH8, 0.05% 
Tween 20, 0.1% SDS, 14mM BME, 200mM sucrose, 3.18 mL of sterile H20, and 
1 tablet of Roche complete mini EDTA-free protease inhibitor cocktail) was 
added to the leaf material.  The samples were placed on ice and mixed for two 
minutes using a mechanical pestle and centrifuged at 14,000 rpm for fifteen 
minutes at 4°C to obtain the supernatant (soluble fraction).  The pellet (insoluble 
fraction) was resuspended with equal volume of protein extraction buffer and 
sonicated for thirty seconds.  The supernatant and pellet was subjected to 
Bradford analysis to determine total protein concentration and stored at -20°C 
until further use.              
SDS-Page and Immunoblot Analysis 
 Clean Bio-Rad glass plates and casting chamber was set up for SDS-
Page analysis.  12.5% separating gel (4.15 mL of 30% Acrylamide/Bis solution 
(BioRad), 2.5 mL of 4X Separating Buffer: 5M Tris-HCl, pH 8.8, 3.2 mL of H20, 
0.1 mL of 10% SDS, 0.1 mL of 10% APS, and 10 µL of TEMED) was mixed in a 
50 mL beaker and by using a syringe it was added in between the two glass 
plates leaving about 1.5 cm empty for the stacking gel.  Immediately water was 
added to the top of the separating gel and allowed to polymerize for thirty 
minutes.  The water was removed with a Kim wipe and 4% stacking gel (665 µL 
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of 30% Bio Rad Acrylamide/Bis solution, 1.25 mL of 4X Stacking Buffer: 0.5M 
Tris-HCl, pH 6.8, 3.0 mL of H20, 50 µL of 10% SDS, 50 µL of 10% APS, and 5 µL 
of TEMED) was prepared.  The 4% stacking gel mixture was layered on top of 
the resolving gel and a comb was inserted for the formation of wells.  After 
polymerization for thirty minutes, the gel was put vertically into the PAGE 
apparatus with 1X Protein Buffer (10X Protein Buffer: 0.25M Tris Base, 1.92M 
Glycine, and 1% SDS).  The protein samples (wild type plants, transgenic plants, 
monomeric CTB (Sigma C9903), and E.coli-derived CTB MSP-1) were prepared 
by the following: 12 µL of protein extract and 12 µL of 2X gel loading buffer (2.5 
mL of 4X Stacking Buffer, 4 mL of 10% SDS, 2 mL of Glycerol, 40 µL of 5% 
Bromophenol Blue, 0.31 g of DTT in a total of 10 mL of distilled H20).  The 
protein samples were boiled for 5 minutes and loaded into the wells along with 7 
µL of Precision Plus Protein Standard (BioRad).  The gel was run at 85 Volts until 
the protein samples entered into the Separating Buffer and the voltage was 
increased to 150 Volts until the dye front reached the bottom of the gel.  The 
proteins from the SDS-PAGE were transferred overnight at 4°C to a HyBond 
nitrocellulose membrane via the Bio Rad Transfer Cassette using Transfer Buffer 
(200 mL of methanol, 100 mL of 10X Protein Buffer, and 700 mL of H20) and 20 
Volts.  
 For immmunoblot analysis, the membrane was washed three times for five 
minutes each with PBS-T and blocked for one hour in 5% PTM at room 
temperature.  Primary antibody, Anti-Cholera Toxin produced in rabbit (Sigma), 
was diluted 1:4,000 in 5% PTM and incubated at room temperature for two 
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hours.  The membrane was washed three times for ten minutes each with 5% 
PTM.  Secondary antibody, Stabilized Goat Anti-Rabbit Horseradish Peroxidase-
Conjugated (PIERCE), was diluted 1:5,000 in 5% PTM and incubated at room 
temperature for one hour.  Blots were washed with PBS-T two times for ten 
minutes each and a final wash of PBS for ten minutes.  The membrane was 
incubated for five minutes in the dark using SuperSignal West Femto Maximum 
Sensitivity Substrate (PIERCE).  The membrane was exposed to Classic Blue 
Autoradiography Film (MIDSCI) in the dark room and the films were developed 
via the film processor to visualize the bands.  
Protein Quantification of Expressed Proteins 
 ELISA was performed to quantify CTB-FC-AMA1 and CTB-MSP-1 in plant 
crude extract versus using densitometric analysis because preliminary ELISA 
results provided a dilution effect in concentration of protein with increasing 
dilutions of the plant extract.  Transgenic leaf samples of mature stages along 
with wild type were quantified.  Total soluble protein was extracted using the 
protocol from the section, extraction of protein from transformed tobacco leaves 
(p.33-34).  CTB (Sigma C9903) was used as the standard and diluted in coating 
buffer (1.59 g of Na2CO3, 2.93 g of NaHCO3, and 0.2 g of NaN3 in 1 L of water; 
adjusted to pH 9.6 using HCl) ranging from 500-25 pg.  Total soluble protein 
extracted from wild type non-transgenic plants, CTB-FC-AMA-1 plants, and CTB-
MSP-1 plants was diluted 1:10, from 1:50,000 – 1:200,000, and from 1:25,000 – 
1:150,000 in coating buffer, respectively.  A 96 well plate (CoStar EIA/RIA plate, 
flat bottom without lid ELISA plate) was coated with 100 µL of CTB standards 
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and test samples and incubated overnight at 4°C.  The next day, the plate was 
washed three times with PBS-T and three times with water.  The plate was 
blocked with 300 µL of 3% PTM and incubated for one hour at 37°C.  The plate 
was washed and 100 µL of primary antibody, Anti-Cholera Toxin produced in 
rabbit (Sigma), was diluted 1:4,000 in 3% PTM and incubated for one hour at 
37°C.   Following primary antibody, the plate was washed and secondary 
antibody, Horseradish Peroxidase-Conjugated Donkey Anti-Rabbit (BioMedia), 
was diluted 1:12,500 in 3% PTM and incubated for one hour at 37°C.  The plate 
was washed and 100 µL of the substrate, TMB (American Qualex Antibodies), 
was added and incubated at room temperature for 5 minutes.  The reaction was 
stopped with 50 µL of 2N sulfuric acid and the plates were read at 450nm with 
the BioRad microplate reader, Model 680.  A Bradford assay using the Bradford 
reagent (Bio-Rad Protein Assay), BSA standards ranging from 0-8 µg/µL, 
absorbance of 595 nm, and the SmartSpecPlus Spectrophotometer (BioRad) 
was used to determine total soluble protein extracted from the wild type and 
transgenic plants. 
 To determine the quantity of chloroplast-derived CTB-FC-AMA1 and CTB-
MSP1 the following equation was used.  The concentration (pg) derived from the 
ELISA multiplied by dilution factor multiplied by 100,000 resulted in concentration 
of transgenic protein in µg.  The concentration of transgenic protein was then 
divided by the volume of sample (100 µL) placed in the well of the ELISA plate.  
The number derived after dividing by the volume plated then was divided by the 
concentration of total soluble protein (provided by Bradford Analysis) and 
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multiplied by 100.  The calculated percentage provides an estimate of the 
chloroplast-derived protein accumulation among all proteins expressed by the 
plant.       
Enrichment of Chloroplast-Derived Proteins 
Immobilized Metal Affinity Chromatography 
 Chloroplast-derived CTB-malarial proteins from transgenic lines was 
extracted by grinding 10 g of plant tissue with a mortar and pestle in liquid 
nitrogen and fine powdered leaf material was placed in a 50 mL tube with a hole 
poked through the top and immediately placed in liquid nitrogen until further use.  
20 mL of plant extraction buffer (100mM NaCl, 200mM Tris-HCl pH8, 0.05% 
Tween 20, 0.1% SDS, 200mM sucrose, 12 mL of sterile H20, and 1 tablet of 
Roche complete mini EDTA-free protease inhibitor cocktail) was added to the 
leaf material. The samples were placed on ice and homogenized for five minutes 
with an OMNI International (GLH-2596) probe and centrifuged at 14,000 rpm for 
fifteen minutes at 4°C to obtain the supernatant (soluble fraction).   
The supernatant (lysate) was subjected to TALON Superflow Metal Affinity 
Resin (Clontech) to enrich the chloroplast-derived CTB-malarial proteins.  The 
manufacture’s protocol, BATCH/Gravity-Flow Column Purification, was followed 
exactly.  The TALON Resin was resuspended thoroughly and 4 mL was placed in 
a sterile 50 mL tube and centrifuged at 700 x g for two minutes to pellet the resin.  
The pellet was pre-equilibrated twice with ten bed volumes of 1X Wash Buffer 
(2.5 mL of 4X Wash Buffer: 0.12M dibasic Na2HPO4, 0.08M monobasic 
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NaH2PO4, 1.2M NaCl, 4% Tween-20, made up to 100 mL of sterile H20, pH8; 
20mM Imidazole, sterile H20 was added to make up the volume to 10 mL, and 1 
tablet of Roche complete mini EDTA-free protease inhibitor cocktail).  The plant 
extract was added to the resin and agitated at 4°C for two hours.  The mixture 
was centrifuged at 700 x g for five minutes and the supernatant (flow through) 
was removed carefully without disturbing the resin.  The mixture was washed 
twice with ten bed volumes of 1X Wash Buffer and the supernatant was 
discarded.  2 mL of 1X Wash Buffer was added to the resin and transferred to a 2 
mL gravity-flow column with an end-cap in place.  The end cap was removed and 
the buffer was allowed to drain.  The column was washed once with five bed 
volumes of 1X Wash Buffer.  To elute the chloroplast-derived CTB-malarial 
proteins, five bed volumes of Elution Buffer (2.5 mL of 4X Wash Buffer, 20 mM 
Imidazole, 100 mM EDTA, volume made up to 10 mL of sterile H20, and 1 tablet 
of Roche complete mini EDTA-free protease inhibitor cocktail, pH8) was added 
and the elute fraction was collected.  The eluted fraction collected along with wild 
type material, lysate, flow through, and wash was analyzed with a Bradford and 
the Bio-Rad RC-DC Protein Assay to determine protein concentration.  The 
eluted fractions were dialyzed with 1X sterile PBS and the Slide-A-Lyzer Dialysis 
Cassette 10,000 MW (PIERCE).     
Analysis of Chloroplast-Derived CTB-Malarial Protein Enrichment 
 The eluted, wild type material, lysate, flow through, and wash fractions 
were subjected to a gradient gel and immunoblot to determine the efficiency of 
enrichment.  7 µg of the CTB FC AMA-1 fractions under reduced and non-
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reduced conditions were heated at 70°C for ten minutes and loaded into a 
NuPAGE Novex Bis Tris Gel (Invitrogen) and electrophoresed at 200 Volts until 
the dye front reached the bottom of the gel.  The gel was rinsed in water and 
stained overnight with the GelCode Blue Stain Reagent (PIERCE).  5 µg of the 
CTB FC AMA-1 and CTB MSP-1 fractions (eluted, wild type, lysate, flow through, 
wash) were electrophoresed and analyzed by an immunoblot.  The primary 
antibody, Anti-Cholera Toxin produced in rabbit (Sigma), diluted 1:4,000 in 5% 
PTM, was incubated at room temperature for two hours.  Secondary antibody, 
Stabilized Goat Anti-Rabbit Horseradish Peroxidase-Conjugated (PIERCE), 
diluted 1:5,000 in 5% PTM, was incubated at room temperature for one hour.  
Following incubation with substrate, membranes were exposed to X-ray film and 
developed via the film processor to visualize the bands.  
Densitometry 
An immunoblot of the eluted chloroplast-derived CTB-malarial proteins 
and known quantities of CTB protein was analyzed by using spot densitometric 
analysis.  1000, 500, 250, 125 ng of CTB protein (Sigma, C9903) and 1.5, 0.75, 
0.375, 0.1875 µg of eluted CTB FC AMA-1 and 1.5, 0.75, 0.375 µg of eluted CTB 
MSP-1 was electrophoresed and analyzed by an immunoblot.  The primary 
antibody added was rabbit anti-CTB and the secondary antibody was goat anti-
rabbit.  Following exposure to film, the blots with known CTB concentrations and 
eluted fractions were analyzed by using the AlphaImager and AlphaEase FC 
Software (Alpha Innotech).  The concentration of the enriched fraction the 
program calculated was divided by the known concentration of the enriched 
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fraction loaded and multiplied by one hundred to determine efficiency of the talon 
enrichment.   
Adsorption of Enriched Protein to Adjuvant 
  Chloroplast-enriched proteins (~2.5 mg) derived from transgenic tobacco 
crude extract was mixed with 1:4 diluted Alhydrogel in PBS (Aluminum Hydroxide 
Gel, Sigma) and incubated overnight with gentle rocking at 4°C.  The samples 
were centrifuged at 2,000 x g for five minutes at 4°C.  The RC-DC Protein Assay 
(BioRad) was used to determine the adsorption efficiency by comparing the total 
amount of protein added to the adjuvant and the protein remaining in the 
supernatant after binding to adjuvant.  The protein-adsorbed pellet was 
resuspended in sterile PBS to a final concentration of 1 µg/µL. 
Immunizations 
For subcutaneous injections 100 µL of Alhydrogel or chloroplast-derived 
protein adsorbed to Alhydrogel was injected into the scruff of the neck using a 
tuberculin syringe fitted with a 27-G needle.  The leaf material for the doses for 
oral delivery was previously ground in liquid nitrogen with mortars and pestles 
and stored at -80°C until the day of immunization.  Oral doses (500 mg each) of 
either wild type or transgenic leaf material was resuspended in 200 µL of sterile 
PBS and homogenized on ice for five minutes with an OMNI International (GLH-
2596) probe.  The plant cell suspension was stored on ice until oral delivery.  200 
µL of the plant cell suspension was delivered via oral gavage by using a 
tuberculin syringe and a 20-G bulb-tipped gastric gavage needle.       
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Ninety female BALB/c mice were purchased at 7 weeks from Charles 

























able 1: Schedule of Immunization of Mice 
Group Immunization 
Type 
Immunization Sample Route of 
Administration 







Boost WT PH Oral 
 
 
Days 10, 17, 24, 
31, 37, 45, 52, 





Boost AlH s.c. Days 13, 27, 43, 





Prime enCTB FC AMA-1 s.c. Day 0 25 µg 
Boost enCTB FC AMA-1 s.c. Days 13, 27, 43, 





Prime enCTB FC AMA-1 s.c. Day 0 25 µg 
Boost CTB FC AMA-1 Oral Days 10, 17, 24, 
31, 37, 45, 52, 






Prime enCTB MSP-1 s.c. Day 0 25 µg 
Boost enCTB MSP-1 s.c. Days 13, 27, 43, 




Prime enCTB MSP-1 s.c. Day 0 25 µg 
Boost CTB MSP-1 Oral Days 10, 17, 24, 
31, 37, 45, 52, 




Prime enCTB FC AMA-1 
enCTB MSP-1 
s.c. Day 0 25 µg 
Boost enCTB FC AMA-1 
enCTB MSP-1 
s.c. Days 13, 27, 43, 





Prime enCTB FC AMA-1 
enCTB MSP-1 
s.c. Day 0 25 µg 
Boost CTB FC AMA-1  
CTB MSP-1 
Oral Days 10, 17, 24, 
31, 37, 45, 52, 
59, 150, 157, 189 
500 mg*** 
9 Nothing Nothing Nothing Nothing 0 µg 
10 Mice Per Group: 90 mice Total 
WT PH: Non-transgenic tobacco plants 
AlH: Alhydrogel (Adjuvant) 
Oral: Oral gavage 
s.c: Subcutaneous injection 
enCTB FC AMA-1: Enriched CTB FC AMA-1 
CTB FC AMA-1: Transgenic tobacco plants expressing CTB FC AMA-1 
enCTB MSP-1: Enriched CTB MSP-1 
CTB MSP-1: Transgenic tobacco plants expressing CTB MSP-1 
***ORAL DELIVERY: Leaf material not antigen
  37
Determination of Antibody Titers from Serum Samples 
Blood Samples Collection 
Blood samples were obtained on days 21, 35, 63, 163, and 197-post 
immunization.  The mouse was restrained and blood was collected by inserting a 
golden rod animal lancet 4mm, 5mm, or 5.5mm, depending on the age and size 
of the mouse, in the submandibular vein.  The blood was collected in Microtainer 
serum separation tubes (Becton-Dickinson) and allowed to clot for a minimum of 
30 minutes at room temperature.  The blood samples were centrifuged at 15,000 
rpm for 5 minutes and the serum was transferred to new microcentrifuge tubes 
and stored at -80°C.   
ELISA to Determine Antibody Titers 
 96 well plates (CoStar EIA/RIA plate, flat bottom without lid ELISA plate) 
were coated with 100 ng of CTB (Sigma C9903) or 50 ng of MRA-49 PfMSP119 
protein in coating buffer (1.59 g of Na2CO3, 2.93 g of NaHCO3, and 0.2 g of NaN3 
in 1 L of water; adjusted to pH 9.6 using HCl) per well.  The plates were 
incubated overnight at 4°C.  The following day, the plates were washed three 
times with PBS-T and water and blocked with PBS containing 0.1% Tween and 
3% skim milk powder for one hour at 37°C.  The following dilutions were 
prepared in PTM to determine CTB titers for all control and experimental mice: 
bleed #1 ranging from 1:1,000 to 1:50,000; bleed #2 ranging from 1:25,000 to 
1:150,000; bleed #3 ranging from 1:50,000 to 1:400,000; and bleeds #4 and #5 
ranging from 1:100,000 to 1:800,000.  For quantification of MSP-1 titers, the 
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serum samples from groups 5, 6, and 9 (unimmunized) were diluted in PTM with 
the following dilutions: bleed #1 and #2 ranging from 1:100 to 1:1000; bleed #3 
from 1:250 to 1:25,000; bleed #4 from 1:500 to 1:25,000; and bleed #5 from 
1:1000 to 1:50,000.  The plates were washed and incubated with 100 µL of 
diluted serum samples (in duplicate) and incubated for one hour at 37°C.  The 
plates were washed and incubated with 100 µL of 1:5,000 diluted goat anti 
mouse IgG1 (American Qualex) conjugated with horseradish peroxidase enzyme 
in PTM for one hour at 37°C.  The plates were washed and 100 µL of TMB 
substrate (American Qualex Antibodies) was added and incubated at 37°C for 
thirty minutes.  The reaction was stopped with 50 µL of 2N sulfuric acid and the 
plates were read at 450nm with the plate reader (BioRad microplate reader, 
Model 680).  The titer values were determined by using the O.D. (optical density) 
of the negative control (unimmunized mice, group 9) + 0.1.        
Immunoblot for Detection of Anti-Malarial Antibodies from Serum Samples 
 The immunoblot protocol followed was mentioned above in the 
characterization of chloroplast-derived proteins (p.34-35).  The protein samples 
loaded into the SDS-PAGE gel were isolated prior and stored in the -80° freezer.  
36.8 µg of ring, trophozoite, and schizont stage proteins were electrophoresed 
and analyzed by an immunoblot.  The primary antibody, sera collected from an 
immunized mouse from groups 3 and 5, used was diluted 1:100 in 5% PTM. 
Secondary antibody, Stabilized Goat Anti-Mouse Horseradish Peroxidase-
Conjugated (PIERCE), was diluted 1:5,000 in 5% PTM.  Following incubation 
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with substrate, membranes were exposed to X-ray film and developed via the 
film processor to visualize the bands.  
IFA for Detection of Anti-Malarial Antibodies from Serum Samples 
 A revised protocol by Tonkin et al. was followed for the preparation and 
fixation of cells (Tonkin, van Dooren et al. 2004) for IFA analysis.  Cells were 
washed once with PBS and fixed in 4% paraformaldehyde and 0.0075% 
glutaraldehyde in PBS for 30 min at room temperature.  Following fixation, cells 
were washed once with PBS and permeabilized with 0.1% Triton X-100 (Sigma) 
for ten minutes and to reduce free aldehydes cells were treated with 0.1 mg/mL 
NaBH4/PBS for ten minutes at room temperature.  Cells were washed once with 
PBS and finally blocked with 3% BSA/PBS for one hour at room temperature.  
Cells were probed with antibodies, (sera obtained from a immunized mouse in 
group 3 and 5) diluted 1:500 in 3% BSA/PBS for two hours at room temperature 
followed by three washes with PBS.  The secondary antibodies were Alexa Fluor 
555 goat anti-mouse diluted 1:1000 in 3% PBS containing BSA and inverted in 
the dark for one hour at room temperature.  Cells were washed three times with 
PBS and allowed to settle on previously coated coverslips with 1% PEI for thirty 
minutes at room temperature.  The mounting solution, 50% glycerol with 
0.1 mg/mL DABCO (Sigma) was added to the coverslips and then inverted on 
microscope slides.  Fluorescence images were observed and captured by using 
an LSM 510 confocal laser scanning microscope (Carl Zeiss). 
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In Vitro Parasite Inhibition Assay 
 The 3D7 P. falciparum culture was synchronized with ring stage parasites 
and sorbitol lysis.  The parasite completed one cycle and was allowed to mature 
to the trophozoite-schizont stage.  The hematocrit and parasitemia were adjusted 
to 2% (2.5% parasitemia for the MRA-35 PfMSP119 in vitro parasite inhibition 
assay).  Mouse sera and MRA-35 PfMSP119 (positive control) were heat 
inactivated at 56°C for 30 minutes and absorbed with human RBCs overnight at 
4°C (Sachdeva, Mohmmed et al. 2006).  The mouse serum was added to the 
parasite culture in 96 well plates at a final concentration of 20% (for the MRA-35 
PfMSP119 in vitro parasite inhibition assay 5 µL of antibody was added and 
diluted 1:5 – 1:625 to 25 µL of parasite culture).  To serve as a negative control, 
no serum was added to wells and replaced with culture media.  The cultures 
were incubated for 48 hours to allow for schizont rupture and merozoite invasion.  
These assays were preformed in duplicate.  For microscopic analysis using the 
100X oil immersion lens, blood smears were made and stained with Giemsa and 
the numbers of parasites per 900-1,100 RBCs were determined for each well.  
Parasitemia was measured using the following formula (infected RBCs / 
infected+uninfected RBCs) x 100.  Percent of inhibition was determined by the 
following formula (% parasitemia of no sera added - % parasitemia of 
experimental mouse sera / % parasitemia of no sera added) x 100.  Relative 
percent of inhibition was determined by the following formula (% of inhibition from 
experimental mouse sera / % inhibition of MRA-35 PfMSP119 (positive control)) x 
100 and the percent of inhibition for the positive control was set at 100%.  
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Pictures were taken from the slides to show the extent of parasitemia and 




Amplification of AMA-1 and MSP-1 in Asexual Stages and CTB 
  To verify AMA1 and MSP-1 expression in 3D7 P. falciparum parasites, 
transcripts were detected by RT-PCR by using total RNA from mixed stages of 
parasites and gene-specific primers (Figure 2).  By using gene-specific primers, 
CTB template DNA, and PCR; CTB was amplified with the expected size as 
shown in Figure 2. 
 
Figure 2: PCR and RT-PCR Analysis of CTB, FC AMA-1, and MSP-1  
DNA was amplified using a single tube PCR and RT-PCR approach and gene 
specific primers as discussed under “Materials and Methods” resulting in Lane 2: 
(CTB, 332 bp), Lane 4: (FC AMA-1, 383 bp), and Lane 6: (MSP-1, 289 bp).  
Molecular size standards are indicated in Lanes 1, 5: 1 kb + ladder and Lane 3: 1 
kb ladder. 
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Cloning Analysis into Chloroplast Vector 
 The inserts, FC AMA-1, MSP-1, and CTB, were successfully cloned into 
the pGMET easy and pBSK+ vectors successfully (data not shown).  The DNA 
sequences were confirmed after successful ligation into the pGEMT easy vector.  
Once the transgene fusions, CTB FC AMA-1 and CTB MSP-1, were constructed 
in the pBSK+ vector, the constructs were excised and ligated into the chloroplast 
pLD-UTR vector with expected sizes as shown in Figure 3.  The constructs were 
then bombarded into the tobacco plant Nicotiana tabacum variety Petit Havana 
by the protocol listed in the “Materials and Methods” section.  
 
Figure 3: Analysis of Cloning CTB FC AMA-1 and CTB MSP-1 Into the pLD-UTR 
Chloroplast Vector 
After purifying plasmid DNA with the Qiagen Plasmid Maxi Kit, the DNA was 
analyzed by gel electrophoresis.  CTB FC AMA-1 is depicted in Lane 3: 
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undigested and Lane 6: digested with NotI and NdeI resulting in a 715 bp 
fragment.  CTB MSP-1 is illustrated in Lane 7: after digestion with NotI and NdeI 
(621 bp fragment).  In Lanes 2, 4, 5: genes were inserted into the pLD-UTR 
vector but were not further studied.   Molecular size standards are indicated in 




















Confirmation of Chloroplast Integration of Transgenes 
 The gene cassette (aadA and CTB FC AMA-1/CTB MSP-1) was 
introduced into the tobacco chloroplast genome through homologous 
recombination of the flanking sequences of the pLD-UTR vector (trnI and trnA) 
and the native plastid genome.  The Prrn downstream of the trnI gene is for 
transcription of aada that confers resistance to spectinomycin and streptomycin 
and the transgene that encodes the CTB-malarial gene.  The 3' UTR upstream of 
the trnA gene provides stability for the transcript and may be involved in 
ribosome recruitment.   
 Five to six resistant shoots appeared on the regeneration media (RMOP) 
containing spectinomycin.  Using specific primers and PCR analysis, mutant and 
nuclear integrated shoots were differentiated from shoots where the transgene 
integrated into the chloroplast genome.  By using 3P/3M primers, site-specific 
integration of the gene cassette was confirmed.  To eliminate all nuclear 
transformants, the 3P primer was used because it annealed to the native 
chloroplast genome.  The 3M primer was used because it landed on the aadA 
gene and eliminated all mutant transformants.  The 3P/3M primers, resistant 
shoots, and PCR analysis yielded a 1.65 kb band as shown in Figure 4 (left 
panels).  Another set of primers 5P/2M were used to confirm the integration of 
the aadA gene and the CTB-malarial gene.  The 5P primer annealed to the aadA 
gene and the 2M primer annealed to the trnA gene.  The amplified PCR product 
size was 2.3 kb for CTB FC AMA-1 and 2.2 kb for CTB MSP-1 as shown in 
Figure 4 (right panels).  The 5P/2M PCR analysis eliminated all mutants and 
only positive transformants with transgene integration were visualized. The 
positive transformants were subjected to second and third round of selection to 
advance towards homoplasmy.              
 
Figure 4: PCR Analysis of Wild Type and Positive Transformants 
PCR using specific primers land within the native chloroplast genome and the 
aadA gene (3P3M) to yield a 1.65 kb product Lanes 2, 14: positive control, 
Lanes 3, 15: wild type, Lanes 4-6: transgenic lines pLD-UTR CTB FC AMA-1, 
and Lanes 16, 17: transgenic lines pLD-UTR CTB-MSP-1.  Using the specific 
5P/2M primers, landing on the aadA gene and trnA gene, respectively yields a 
2.3 kb and 2.2 kb product Lanes 8, 19: positive control, Lanes 9, 20: wild type, 
Lanes 10, 11: negative transformants pLD-UTR CTB FC AMA-1, Lane 12: 
transgenic line pLD-UTR CTB FC AMA-1, and Lanes 21, 22: transgenic lines 
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pLD-UTR CTB-MSP-1.  Molecular size standards are indicated in Lanes 1, 7, 13, 






















Southern Analysis of Transgenic Plants 
 To confirm site-specific integration and homoplasmic plants, 
untransformed and transgenic plant genomic DNA was probed with the 2P/2M 
flanking sequence probe of 1.3 kb in size.  The transgenic and non-transgenic 
genomic DNA was digested with the restriction enzyme ApaI.  After digestion, the 
untransformed chloroplast genome resulted in a 4.5 kb fragment and the 
transformed chloroplast genome resulted in 6.5 and 6.6 kb fragments for CTB 
MSP-1 and CTB FC AMA-1, respectively, as depicted in Figure 5.  The absence 
of the 4.5 kb fragment in the transplastomic lines confirms homoplasmy (Figure 




Figure 5: Evaluation of Transgene Integration into the Chloroplast Genome of 
Homoplasmic Plants by Southern Blot 
Southern blot probed with the 2P/2M flanking sequence probe to determine 
homoplasmy Lane 1: wild type, Lane 2: homoplasmic CTB MSP-1 (6.5 kb), and 



















Selection and Generation of Transgenic Plants 
 Transgenic plants were selected and generated by the use of RMOP 
media and spectinomycin (Figure 6A).  After positive transformants were 
determined by PCR analysis, further selection and generation of transgenic 
shoots was maintained (Figure 6B).  MSO selection media containing 
spectinomycin was used for rooting.  Once the in vitro plants were confirmed 
homoplasmic by Southern Blot analysis the plants were transferred to the 
greenhouse for optimal growth and maximal protein expression (Figure 6C).  No 
pleiotropic effects were observed with the transgenic plants (CTB FC AMA-1, 
middle plant and CTB MSP-1, right plant) in comparison with untransformed 




Figure 6: Generation of Transgenic Plants 
(A) Four to five weeks after particle bombardment, transplastomic shoots appear 
on RMOP selection medium.  For second round of selection, leaves from PCR 
positive transformants are transferred to RMOP selection medium.  (B) Several 
shoots appear within two to three weeks.  For third round of selection, 
regenerated shoots are transferred to MSO selection medium and roots appear 
in about 10 days.  (C) Plants were transferred to the greenhouse after 
confirmation of homoplasmic plants via Southern blot analysis.  In the picture, 
from left to right the following plants are visualized: untransformed control, CTB 


























Characterization of the Chloroplast-Derived CTB Malarial Proteins 
 Crude extracts of approximately 50 µg of wild type and transgenic plants 
along with monomeric CTB protein and an E.coli expressed CTB MSP-1 extract 
were loaded in the wells of a SDS-PAGE gel.  The blots were probed with the 
polyclonal anti-CTB primary antibody and the monomeric forms of CTB FC AMA-
1 showed a 27.5 kDa protein and CTB MSP-1 depicted a 23 kDa protein in the 
insoluble (pellet) and soluble (supernatant) fractions (Figure 7).  The immunoblot 
displayed others forms of the CTB-malaria proteins such dimers, trimers, 
tetramers, and pentamers (Figure 7).    
 
 
Figure 7: Immunoblot Analysis to Confirm Expression of CTB-Malarial Antigens 
in Nicotiana tabacum Crude Extracts 
Immunoblot with anti-CTB polyclonal antibody showed full-length protein.  Lanes 
1, 5: negative control wild type extract, Lane 2: positive control monomeric 11.6 
kDa CTB protein, Lane 6: positive control CTB MSP-1 E. coli expressed protein, 
Lane 3: CTB FC AMA-1 pellet, Lane 4: CTB FC AMA-1 supernatant, Lane 7: 
CTB MSP-1 pellet, and Lane 8: CTB MSP-1 supernatant.  
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Quantification of Chloroplast-Derived CTB Malarial Proteins 
 To determine the concentration of the chloroplast derived CTB-malarial 
proteins, a standard ELISA was performed.  Using CTB protein of known 
concentrations, a standard curve was generated as depicted in Figure 8 (top 
panel).  The ELISA displayed a dilution effect with the diluted crude plant extracts 
and the standard curve (data not shown).  The CTB FC AMA-1 and CTB MSP-1 
protein expression levels of mature leaves reached 6.3-9.5% and 1.4-2%, 
respectively as shown in Figure 8 (bottom panel).  The accumulation of the CTB-
malarial proteins in high level of expression is due to the presence of high 




Figure 8: Quantification of Chloroplast-Derived CTB-Malarial Expression 
An ELISA with the following expression levels determined quantification: 6.3-







Enrichment of Chloroplast-Derived CTB-Malarial Proteins 
Resolution of Enriched Proteins 
 A crude extract of chloroplast-derived proteins was subjected to 
immobilized metal affinity chromatography by using the TALON Superflow Metal 
Affinity Resin and analysis followed.  A NuPAGE Novex Bis-Tris gradient gel was 
used to increase the resolution of the enriched CTB FC AMA-1 protein.  The gel 
was performed under reduced and non-reduced conditions.  The large subunit of 
rubisco (55 kDa) is apparent in the wild type, lysate, and flow through fractions 
under reduced and non-reduced conditions (Figure 9).  In the wash fractions 
there are minimal bands present.  In the eluted CTB FC AMA-1 fraction, the 
monomer of 27.5 kDa in size is present under reduced conditions (Lane 6) and 
the pentameric form is present under both reduced (Lane 6) and non-reduced 





Figure 9: Increased Resolution of Chloroplast-Derived CTB FC AMA-1 Protein 
After Immobilized Metal Affinity Chromatography 
CTB FC AMA-1 protein was extracted from transformed leaves and the crude 
extract was subjected to Talon Superflow Metal Affinity Resin and analyzed.  
Lanes 2-6: reduced and Lanes 8-12: non-reduced conditions of CTB FC AMA-1 
protein enrichment was observed by using a gradient gel (4-12%) and gel 
electrophoresis.   The following fragments were visualized Lanes 2, 8: wild type, 
Lanes 3, 9: lysate, Lanes 4, 10: flow through, Lanes 5, 11: wash, and Lanes 6, 
12: enriched protein.  Molecular size standards are indicated in Lanes 1, 7: 1 kb 
ladder.     
























Immunoblot Analysis of Enriched Proteins 
 An immunoblot probed with anti-CTB antibody was conducted to confirm 
the presence of the CTB-malarial proteins after talon enrichment.  Equal amounts 
of protein from wild type, lysate, flow through, wash, and enrichment was loaded 
into the gel and visualized via an immunoblot.  In the fractions containing protein 
harvested from wild type leaves resulted in no apparent band in the immunoblot 
analysis (Figure 10).  Lower levels of CTB-malarial proteins were found in the 
flow through and wash fractions compared to the lysate and in the enriched 
fractions significant protein expression were found confirming enrichment of the 
CTB-malarial proteins (Figure 10).    
 
Figure 10: Immunoblot Analysis of Enrichment of Malarial Antigens from 
Nicotiana tabacum Extracts 
Malaria protein was extracted from transformed leaves and the crude extract was 
subjected to Talon Superflow Metal Affinity Resin and the following fractions 
were collected and analyzed using an immunoblot with polyclonal anti-CTB 
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antibody: Lanes 1, 6: wild type, Lanes 2, 7: lysate, Lanes 3, 8: flow through, 








































 An immunoblot with known concentrations of CTB protein and different 
concentrations of the enriched fractions were probed with anti-CTB antibody.  
Quantification of the enriched CTB-malarial proteins on immunoblots was 
analyzed by spot densitometry.  Linearity of the standard curve was achieved by 
using 1000, 500, 250, and 125 ng of CTB (data not shown) and assisted in the 
estimation of the enriched samples in the same blot (Figure 11).  The standard 
curve provided the concentration of the enriched fractions and the efficiency of 
the talon enrichment was determined to be 90% and 73% in CTB FC AMA-1 and 
CTB MSP-1, respectively.   
 
 
Figure 11: Immunoblot of the Eluted Protein Fractions were Analyzed and 
Compared to Known Quantities of CTB Protein 
Immunoblot analysis of Lanes 1-4 and 10-13: CTB protein (1000, 500, 250, 125 
ng, respectively), Lanes 6-9: eluted CTB FC AMA-1 (1.5, 0.75, 0.375, 0.1875 µg, 
respectively), and Lanes 14-16: eluted CTB MSP-1 (1.5, 0.75, 0.375 µg, 
respectively).  Eluted proteins and CTB were subjected to densitometry to 
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determine the enrichment of CTB FC AMA-1 and CTB MSP-1 to be administered 






















Immunogenicity of the Chloroplast-Derived CTB Malarial Antigens  
Quantitation of CTB Titers from Immunized Mice 
 The serum collected from the five bleeds following immunization were on 
days 21, 35, 63, 163, and 197-post immunization.  The serum was tested for anti-
CTB antibodies by a capture ELISA with CTB protein.  Minimal mice titers were 
detected from bleeds #1 and #2 ranging from 1:1,000 – 1:150,000 and titers were 
present ranging from 1:50,000 – 1:800,000 in bleeds #3, #4, and #5 (Figure 12).  
Titers for anti-CTB were found to be higher in groups 3, 5, 6, 7, and 8 versus 
group 4 (oral delivery CTB FC AMA-1) (Figure 12).  No CTB titers were found for 
group 1 (oral delivery non-transgenic leaf material) or group 2 (subcutaneous 
injection alhydrogel alone).  
 
Figure 12: Immunogenicity of CTB Titers Using a Capture ELISA 
ELISA detection of anti-CTB antibody titers from groups 1 – 8 serum samples 






Quantitation of MSP-119 Titers from Groups 5 and 6  
The serum collected from the five bleeds following immunization was 
tested for anti-PfMSP119 antibodies by a capture ELISA with MRA-49 PfMSP119.  
Minimal mice titers were detected from bleeds #1 and #2 and titers were present 
ranging from 1:100 – 1:50,000 in bleeds #3, #4, and #5 (Table 2).  Titers for anti-
PfMSP119 were found to be higher in group 5 (subcutaneous injection) than in 
group 6 (oral delivery) (Table 2).  Four mice in groups 5 and 6 (5A1, 5B3, 6A1, 
6B4) showed undetectable titers with MRA-49 PfMSP119 protein (Table 2) but 
















Table 2: Immunogenicity of a Malarial Antigen Using MSP-1 Protein 






Titers Bleed #4 
MSP-1 IgG1 
Titers Bleed #5
5A1 0 0 0 0 0
5A2 100 1000 25000 25000 50000
5A3 1000 1000 25000 25000 25000
5A4 100 1000 12500 25000 50000
5A5 0 1000 1000 1000 1000
5B1 0 0 250 1000 12500
5B2 100 1000 12500 25000 25000
5B3 0 0 0 0 0
5B4 0 1000 25000 25000 50000
5B5 0 0 1000 1000 12500
6A1 0 0 0 0 0
6A2 0 500 1000 12500 12500
6A3 100 250 1000 12500 12500
6A4 100 1000 1000 1000 1000
6A5 0 0 250 1000 1000
6B1 0 0 250 1000 1000
6B2 500 1000 12500 12500 12500
6B3 0 100 1000 1000 1000
6B4 0 0 0 0 0
6B5 0 250 1000 12500 12500
 
ELISA detection of anti-MSP-1 antibody titers from groups 5 and 6 serum 






Recognition of Parasite Protein by Anti-Malarial Antibodies 
 An immunoblot confirmed anti-malarial antibodies from immunized mice 
recognized parasite protein from P. falciparum infected erythrocytes.  Anti-AMA-1 
antibodies, sera collected from a mouse immunized with CTB FC AMA-1 antigen, 
recognized the ring and schizont stages with the presence of an 83 kDa band 
(Figure 13).  The serum from an immunized mouse from group 5 contained anti-
MSP-1 antibodies, which recognized ring and schizont stages with an apparent 
190 kDa band (Figure 13).     
 
 
Figure 13: Recognition of Parasite Protein by Anti-AMA-1 and Anti-MSP-1 
Antibodies 
36.8 µg of ring, trophozoite, and schizont parasite protein was loaded into the 
SDS PAGE gel and analyzed by an immunoblot with 1:1,000 diluted sera from 
immunized mice.  Immunoblot displaying Lanes 1-3: anti-AMA-1 collected from 
an immunized mouse recognizes 83 kDa AMA-1 protein and Lanes 4-6: anti-
MSP-1 recognizes 190 kDa MSP-1 protein.  The parasite stages analyzed from 
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the 3D7 P. falciparum culture include Lanes 1, 4: ring, Lanes 2, 5: trophozoite, 





















Recognition of Parasite by Anti-Malarial Antibodies 
 Sera collected from immunized mice with chloroplast-derived CTB-malarial 
antigens resulted in the recognition of parasite localization.  Anti-AMA-1 
antibodies were found in the immunized sera because parasites were stained in 
the apical end of the ring stage parasite (Figure 14 B, C).  A mouse immunized 
with the chloroplast-derived CTB-MSP-1 antigen resulted in stained schizonts 
indicating the presence of anti-MSP-1 antibodies (Figure 14 E, F).     
 
Figure 14: Recognition of Parasite by Anti-AMA-1 and Anti-MSP-1 Antibodies 
Visible and immunofluorescence (IFA) images of 3D7 P. falciparum parasite 
immunostained with (A, B, C) anti-AMA-1 raised in mice displaying recognition of 
the apical end of the parasite and (D, E, F) anti-MSP-1 collected from immunized 
mouse sera recognizing the MSP-1 of a schizont parasite. 
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In Vitro Parasite Inhibition Assay 
Anti-AMA-1 and Anti-MSP-1 Antibodies Prevent Invasion 
 An in vitro parasite inhibition assay was performed to test the ability of 
anti-AMA-1 and anti-MSP-1 antibodies in inhibiting parasite entry into 
erythrocytes.  Synchronized trophozoite-schizont stage parasites (2% 
parasitemia and hematocrit, Figure 15 A) were incubated with control and test 
sera for forty-eight hours and blood smears were made.  The slides were stained 
with Giemsa and the number of parasites and total number of RBCs were 
counted.  The parasitemia was determined and the percent inhibition was 
calculated.  The predominant stage found under microscopic examination was 
the ring stage.  The average parasitemia for the blank control (no serum added) 
was determined to be 6.6% (Figure 15 B) while the lowest parasitemia found 
was from group 5, subcutaneous CTB MSP-1 (2.5%, Table 3) and in mouse 5A4 
with the highest MSP-119 titer of 50,000 (2.4%, Figure 15 C) representing the 
group and the mouse with highest percent of relative inhibition to the positive 
control (117.2%, Table 3) and percent of inhibition (63.6%, Table 4), 
respectively, of parasite invasion.  The remaining experimental groups displayed 
85.8 – 105.8% relative inhibition to the positive control (Table 3).  The control 
groups who did not receive chloroplast-derived CTB-malarial antigen resulted in 
14.3 – 25.7% relative inhibition to the positive control (Table 3).  The immunized 
mouse, 6B3, with the lowest MSP-119 titer of 1,000 was found to exhibit the 
highest parasitemia (3.5%, Figure 15 D) after the in vitro parasite inhibition 
assay.  The serum from the positive control (MRA-35 rabbit antiserum against 
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purified recombinant yeast secreted PfMSP1-19, 3D7) resulted in only 53% 
inhibition (Table 4).  The control groups (groups 1, 2, 9) resulted in 7.6 – 13.6% 
inhibition and mice 5B5 and 6B5 with a MSP-119 titer of 12,500 resulted in 59.1% 
and 54.5%, respectively (Table 4).  
 
Table 3: Calculation of Average Parasitemia and Relative Inhibition of 
Experimental Mice Sera After an in Vitro Parasite Inhibition Assay 
 
Group Parasitemia Mean Parasitemia Relative Inhibition
No Ab 6.6 - 6.7% 6.6% - 
MRA-35 PfMSP1-19 2.5 - 3.5% 3.1% 100.0% 
Group 1 5.9 - 6.6% 6.1% 14.3% 
Group 2 5.5 - 6.2% 5.8% 22.8% 
Group 3 2.8 - 3% 2.9% 105.8% 
Group 4 2.4 - 3.3% 3.0% 102.8% 
Group 5 2.4 - 2.6% 2.5% 117.2% 
Group 6 2.6 - 3.6% 3.2% 97.2% 
Group 7 2.7 - 3.9% 3.3% 94.3% 
Group 8 3.3 - 3.8% 3.6% 85.8% 
Group 9 5.6 - 5.8% 5.7% 25.7% 
 
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture (2% 
parasitemia and hematocrit) and no sera, MRA-35 PfMSP1-19 sera, and 
immunized mouse sera was incubated for 48 hours; the parasitemia was 
estimated and relative percent of inhibition was determined in comparison to the 
positive control. 
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Table 4: Calculation of Average Parasitemia and Percent Inhibition of Selected 




 Titer Parasitemia Inhibition 
No Ab (Control) – 6.6% – 
MRA-35 PfMSP1-19 
 
– 3.1% 53% 
Group 1 0 6.1% 7.6% 
Group 2 0 5.8% 12.1% 
Mouse 5A4 (s.c.) 50000 2.4% 63.6% 
Mouse 5B5 (s.c.) 12500 2.7% 59.1% 
Mouse 6B3 (oral) 1000 3.5% 47% 
Mouse 6B5 (oral) 12500 3.0% 54.5% 
Group 9 0 5.7% 13.6% 
 
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture (2% 
parasitemia and hematocrit) and no sera, MRA-35 PfMSP1-19 sera, and 
immunized mouse sera was incubated for 48 hours; the parasitemia was 









Figure 15: Microscopic Examination of the in Vitro Parasite Inhibition Assay 
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture 2% 
parasitemia and hematocrit (A), and no sera (B), sera from mouse 5A4 (C), and 
sera from mouse 6B3 (D) was incubated for 48 hours; the parasitemia was 








Anti-MRA-35 PfMSP1-19 Antibodies Prevent Invasion 
An in vitro parasite inhibition assay was performed to test the ability of 
anti-MRA-35 PfMSP1-19 antibodies inhibiting parasite entry into erythrocytes in a 
dose-dependent manner.  Synchronized trophozoite-schizont stage parasites 
(2.5% parasitemia and 2% hematocrit, Figure 16 A) were incubated with 5 µL 
and diluted 1:5-1:625 MRA-35 PfMSP1-19 antibodies for forty-eight hours and 
blood smears were made.  The slides were stained with Giemsa and the number 
of parasites and total number of RBCs were counted.  The parasitemia was 
determined and the percent inhibition was calculated.  The predominant stage 
found under microscopic examination was the ring stage.  The average 
parasitemia for the blank control (no serum added) was determined to be 8.0% 
(Table 5, Figure 16 B) while parasitemia ranged from 3-5.5% and the percent of 
inhibition ranged from 62.5-31.3% from least to most diluted sera, respectively 











Table 5: Calculation of Average Parasitemia and Percent Inhibition After in Vitro 
Parasite Inhibition Assay Using Different Dilutions of MRA-35 PfMSP-1-19 
Antibody 
Group Parasitemia Average 
Parasitemia 
Inhibition 
Blank (Control) 6.9-8.9% 8.0% –  
5 µL  2.7-3.3% 3.0% 62.5% 
1:5 Dilution 3.4-3.8% 3.6% 55% 
1:25 Dilution 4-4.4% 4.2% 47.5% 
1:125 Dilution 4.3-5.1% 4.8% 40.0% 
1:625 Dilution 5.4-5.7% 5.5% 31.3% 
 
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture (2.5% 
parasitemia and 2% hematocrit); no sera or MRA-35 PfMSP1-19 sera was 









Figure 16: Microscopic Examination of the in Vitro Parasite Inhibition Assay After 
Adding Different Dilutions of MRA-35 PfMSP-1-19 Antibody 
Synchronized 3D7 P. falciparum trophozoite-schizont stage culture 2.5% 
parasitemia and 2% hematocrit (A), and no sera (B), 5 µL of MRA-35 PfMSP1-19 
antibody (C), and 1:625 diluted MRA-35 PfMSP1-19 antibody (D) was incubated 









 Currently, there is no licensed vaccine for the prevention of malarial 
disease despite the vast knowledge of genomics and proteomics of the malaria 
parasite (Sharma and Pathak 2008).  The need for a malarial vaccine is 
imperative because the global burden of the disease is increasing due to drug 
resistance, mosquito’s resistance to insecticides, ineffective control measures, 
re-emergence of the disease, and increased tourism.  Malaria vaccine research 
has investigated several vaccine candidates in clinical trials but with 
disappointing results in low titers and poor efficacy.  Previous studies have lead 
to the discovery of AMA-1 and MSP-1, which are two of the leading asexual 
blood-stage malarial vaccine candidates.  The malarial genes, AMA-1 and MSP-
1, were successfully amplified via PCR along with the transmucosal carrier, CTB.  
CTB was included in the present study because of it’s potential adjuvant activity 
on the immune system and possibility of performing as an oral immunogen (Li 
and Fox 1996).  The fusion CTB-malarial gene cassettes were constructed in the 
pBSK+ vector.   
Malaria antigens have been expressed in several expression systems 
such as in E. coli (Sachdeva, Mohmmed et al. 2006), yeast (Gozalo, Lucas et al. 
1998), and mammalian cells (Burghaus, Gerold et al. 1999) but plants could be 
considered as an alternative in vaccine development because they can reduce 
cost due to the expense of fermentation, purification, processing, cold storage, 
and delivery.  The purpose of expressing the CTB-malarial antigens in the 
chloroplast system was to develop a safer and more effective malarial vaccine.  
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By using the flanking sequences trnI and trnA, the chloroplast pLD-UTR vector 
with the CTB-malarial cassette was integrated into the chloroplast genome via 
homologous recombination.  The pLD-UTR vector contains the aadA gene, which 
codes for the enzyme aminoglycoside 3’ adenyltransferase and transgenic 
shoots were allowed to overcome the selection of spectinomycin (Svab and 
Maliga 1993; Verma and Daniell 2007).  3P/3M and 5P/2M primers along with 
PCR confirmed the integration of the gene cassette into the chloroplast genome.  
The positive transformants were subjected to second and third round of selection 
to remove any remaining wild type cells.  The transgenic plants were confirmed 
to be homoplasmic (presence of only transformed genomes) after performing 
southern blot analysis with a flanking sequence probe.  
 The expression of CTB FC AMA-1 and CTB MSP-1 was driven by the psbA 
5’UTR in transgenic lines and confirmed by an immunoblot.  The proteins were 
observed at 27.5 kDa in CTB FC AMA-1 and 23 kDa in CTB MSP-1 in both the 
insoluble (pellet) and soluble (supernatant) fractions as seen in Figure 7.  Along 
with the expression of the CTB-malarial monomer, the immunoblot displayed 
other forms such as dimers, trimers, tetramers, and pentamers.  The expression 
levels in mature leaves of CTB FC AMA-1 and CTB MSP-1 protein reached 6.3-
9.5% and 1.4-2%, respectively as shown in Figure 8.  The expression level of 
CTB FC AMA-1 and CTB MSP-1 is comparable to CTB-Pins in lettuce of 1.8% 
TSP (Ruhlman, Ahangari et al. 2007) but higher levels were seen with 14.8% 
accumulation of F1-V (Arlen, Singleton et al. 2008), 14% of anthrax protective 
antigen (Koya, Moayeri et al. 2005), and 16% of CTB-Pins in tobacco (Ruhlman, 
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Ahangari et al. 2007).  Although lower levels of expression were observed with 
the chloroplast-derived CTB-malarial proteins in tobacco it still provides a 
sufficient level of expression to proceed with animal or preclinical studies 
(Ruhlman, Ahangari et al. 2007).     
The antigen administered to the mice via a subcutaneous injection was 
enriched versus purified because the CTB-malarial protein did not consist of an 
epitope tag for the facilitation of purification.  CTB is known to bind to immobilized 
nickel ions (Dertzbaugh and Cox 1998) and this lead to enriching the CTB-
malarial antigen in plant extracts using nickel beads.  The CTB-malarial antigens 
were successfully enriched with nickel beads and to ensure adequate amounts 
for immunization studies, immobilized metal affinity chromatography using Talon 
Superflow Metal Affinity Resin was used.  The oral-deliverable plant material 
administered to mice was done via oral gavage.   
 Majority of vaccines use the needle-based subcutaneous injection method 
but delivering the antigen via the oral route is a possibility.  Following 
immunization, the immune titers of the mice were determined for mice receiving 
the antigen via the injectable route versus oral boosts.  Immunization studies 
confirmed the chloroplast-derived malarial antigens were immunogenic with 
respect to anti-CTB and anti-MSP-119 antibodies (Figure 12 and Table 2).  The 
titers of groups 3 and 4 in regards to anti-AMA-1 titers were not completed 
because of the lack of AMA-1 protein.  Also, the MSP-1 titers of groups 7 and 8 
were not completed because of the lack of adequate amounts of MSP-1 protein.  
CTB was fused with the malarial antigens because of it’s potential of acting as an 
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oral-mucosal adjuvant (Holmgren, Lycke et al. 1993) and also possibly 
enhancing the immune response (Daniell, Lee et al. 2001).  The mice were found 
to be immunogenic in regards to CTB and the IgG1 titers ranged from 0 – 
1:800,000 with higher titers in bleeds #3, #4, and #5.  High titers were observed 
in experimental groups besides group 4 (oral delivery CTB FC AMA-1) and a 
likely reason for low IgG1 titers is because CTB IgA sera titers were significantly 
higher possibly suppressing the synthesis of IgG1 in these mice (data not 
shown).  Mice titers for IgG1 MSP-119 ranged from 0 – 1:50,000 with higher titers 
in bleeds #3, #4, and #5 and higher titers in group 5 CTB MSP-1 (subcutaneous 
injection) versus group 6 (oral delivery).  Several mice showed no detectable 
MSP-119 titers (two mice each in group 5 and 6) with ELISA analysis (Table 2) 
and a likely explanation is not every mouse responds to the same antigen in the 
same manner but these mice showed similar CTB titers in comparison with the 
other mice in the group.  Higher titers were observed in group 5 compared to 
group 6 because of the challenge to deliver the exact amount of antigen in oral 
gavage to every mouse and titers are expected to be higher when antigen is 
directly introduced into the immune system via an injection.  A reason why the 
titers for MSP-1 were significantly lower than CTB titers may be because malarial 
antigens generally display poor immunogenicity even with the use of an adjuvant 
(Sachdeva, Mohmmed et al. 2006).  Several strategies for optimizing 
immunogenicity of malarial antigens include the use of different adjuvants, 
optimizing immunization protocols, using rabbits or monkeys for animal model 
testing, fusing exogenous viral or bacterial antigens, or constructing multivalent 
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antigen chimeras (Pan, Huang et al. 2004; Qian, Wu et al. 2007; Greenwood, 
Fidock et al. 2008).  The Pf chimeric protein 2.9 (PfCP-2.9) consisting of domain 
III of AMA-1 and 19-kDa C-terminal fragment of MSP-1 was found to be highly 
immunogenic in rabbits and rhesus monkeys by inducing 11 to 18 fold higher 
titers than the individual antigens alone (Pan, Huang et al. 2004).  IFA and 
immunoblots confirmed the presence of anti-AMA-1 and MSP-1 antibodies in the 
sera of immunized mice because of the recognition of parasite and parasite 
protein, as shown in Figures 13, 14.  In the immunoblot analysis, both anti-AMA-
1 and anti-MSP-1 antibodies recognized the ring and schizont stages and this 
follows the expression profiles of AMA-1 and MSP-1 provided by PlasmoDB.  
The same volume of the sera was used for both immunoblots but the intensity 
was greater with using anti-MSP-1 antibodies and this may be due to the titer of 
the mouse immunized with MSP-1 was higher than the mouse immunized with 
AMA-1.  AMA-1 titers were not determined because of the lack of AMA-1 protein 
for ELISA analysis.  
To investigate if the AMA-1 and MSP-1 antibodies mice generate after 
immunization prevents parasite invasion into RBCS, an in vitro parasite inhibition 
assay was performed.  If anti-AMA-1 and anti-MSP-1 antibodies are present in 
the sera collected from immunized mice there should be a decrease in 
parasitemia indicating the inhibition of the parasites from invading RBCs.  In the 
control groups, sera from unimmunized mice and mice immunized with wild type 
leaf material or adjuvant only, similar levels of parasitemia were observed 
compared to control wells incubated with no sera (Table 3).  The relative percent 
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of inhibition in comparison to the positive control (MRA-35 PfMSP1-19) was 
determined for all control and experimental groups because the highest percent 
of inhibition observed for the positive control was 53%.  In comparison to the 
positive control, relative percent of inhibition was found to be the highest in group 
five, subcutaneous CTB MSP-1, (117.2%, Table 3).  Direct correlation of mouse 
titers and percent of parasite inhibition of invasion into RBCs was observed with 
a mouse with a high MSP-119 titer (1:50,000, Table 2) resulting in the greatest 
percent of inhibition (63.6%) in comparison with a mouse with lower titer 
(1:1,000, Table 2) resulting in only 47% inhibition (Table 4).  Other studies have 
found higher percentages of inhibition (Pan, Huang et al. 2004; Arnot, Cavanagh 
et al. 2008) but they incubated parasite culture with purified IgG or isolated 
specific antibodies and did not use whole sera.  A positive control, antibody from 
MR4 (MRA-35 PfMSP1-19), was included in the assay to achieve the greatest 
possible percent of inhibition but only resulted in 53%.  The positive control has 
no known published antibody titer and since it was produced in rabbit the titer 
was not determined because the titer cannot be directly correlated with the titer 
of the immunized mice because the lack of a comparative secondary antibody.  
The results provided from the positive control inefficiently prevented the maximal 
percent of invasion, which proceeded to the experimentation of using different 
dilutions of the antibody and examining a direct comparison of parasitemia levels.  
The most diluted concentration of antibody resulted in about half of the percent of 
inhibition compared to the antibody incubated with the parasite culture at 20%  
(Table 5).  Both in vitro parasite inhibition assays displayed greater inhibition with 
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higher immune titers or antibody concentration compared to lower titers and 
concentration of antibody with less inhibition.   Although the in vitro inhibition 
assay provided evidence that the antibodies generated from mice were effective 
in preventing parasite invasion of RBCs, a more accurate quantification needs to 
be assessed by using an appropriate animal model and a lethal parasite 
challenge (Sachdeva, Mohmmed et al. 2006) because the mice were challenged 
with a rodent malaria strain (Plasmodium berghei) that was generated to express 
the P. falciparum form of MSP-119 (de Koning-Ward, O'Donnell et al. 2003) and 
the challenge was unsuccessful.  One report was found to be successful in 
protecting the mice after the parasite challenge with the P. berghei/P. falciparum 
chimeric line (Pb-PfM19) but they passively immunized the mice with anti-
PfMSP-142 IgG purified from rabbit sera before parasite challenge instead of 
























Malaria is a prominent vector-borne parasitic disease and severe public 
health problem globally, especially prevalent in poor-developing countries.  There 
is a great need to create a low cost human malarial vaccine with the elimination 
of laborious purification techniques and technical skills.  Two leading blood stage 
malarial vaccine candidates AMA-1 and MSP-1 were constructed in a fusion 
cassette with CTB.  The CTB-malarial antigens were expressed in tobacco plants 
via plastid transformation and accumulated to high to moderate levels in CTB FC 
AMA-1 and CTB-MSP-1 to 9.5% and 2% of the total soluble protein, respectively. 
The chloroplast-derived CTB-malarial proteins were administered to mice by 
subcutaneous injection and oral gavage.  The immunogenicities of the CTB and 
MSP-119 antigens were determined to be in the range of 1:1000 – 1:800,000 and 
1:100 – 1:50,000 in mice titers, respectively.  To maximize the MSP-1 titers in 
oral delivery of CTB MSP-1, there needs to a better approach on delivering the 
same quantity of antigen to every mouse.  Sera collected from mice immunized 
with both CTB FC AMA-1 and CTB MSP-1 was found to recognize native 
parasite and native parasite protein via IFA and immunoblot analysis, indicating 
anti-AMA-1 and anti-MSP-1 antibodies were generated in immunized mice.  Anti-
malarial antibodies were found to inhibit parasite invasion into erythrocytes with 
sera collected from immunized mice.  The lack of an appropriate animal model 
needs to be established before in vivo challenge and protection can be 
investigated.  Results of these investigations may lead to further experimentation 
in malarial vaccine development with other malarial antigens and in edible crops. 
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